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Polychlorinated biphenyls (PCBs) are detectable in serum of 100% of adults in US, 
and has been associated with fatty liver disease in epidemiological studies. PCBs are 
classified as either dioxin-like (DL) or non-dioxin-like (NDL) PCB based on their ability 
to activate the aryl hydrocarbon receptor (AhR). We used exposures that reflect human 
bioaccumulation patterns, which resembles Aroclor 1260 with a low level of the DL-PCB, 
PCB 126. Our aim was to determine if this exposure will activate the human and mouse 
AhR and examine if receptor activation influences these steatotic responses due to PCB 
exposures.  
  DL-PCBs exposure-induced AhR activation in luciferase assays and induction of 
AhR target gene expression demonstrated that the Mouse AhR was much more sensitive 
than human AhR to activation by DL-PCBs. Our PCB mixture reflected this by activating 
the mouse AhR, but not human AhR in vivo. The ability of PCBs to activate the AhR would 
be predicted to be WHO toxicity equivalency = rat >mouse >>human.
vi 
 
Mice were exposed to either PCB 126 (20 μg/kg), Aroclor 1260 (20 mg/kg) or both, 
for 2 weeks. PCB 126 or Aroclor 1260/PCB 126 significantly activated AhR, but only PCB 
126 exposure alone induced mild hepatic steatosis. AhR activation suppressed the 
induction of   CAR and PXR targets. More complex patterns of attenuation were observed 
with genes involved in lipid metabolism.  
PCB exposures require a hypercaloric diet to transition steatosis to steatohepatitis in 
murine models. Mice were fed high fat diet and received the same treatments as the 2-week 
study for 12 weeks.  Our PCBs mixture exposure did not induce wasting syndrome, and 
failed to exacerbate steatosis. In addition, PCB 126 exposure activated AhR. Aroclor 1260 
exposure drove hepatic steatosis to steatohepatitis. Either PCB 126 or the Aroclor 
1260/PCB 126 mixture protected against high fat diet induced liver injury and liver fibrosis. 
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1. Non-alcoholic fatty liver disease 
High calorie intake or a Western diet contributes to non-alcoholic fatty liver disease 
(NAFLD), which is manifested by excessive lipid accumulation in liver, termed hepatic 
steatosis. NAFLD encompasses a spectrum of fatty liver diseases, ranging from hepatic 
steatosis to hepatic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular 
carcinoma (HCC) (1). Inflammatory cell infiltration drives hepatic steatosis to progress to 
NASH, which is characterized by hepatic injury, inflammation, oxidative stress and 
fibrosis. Hepatic steatosis and steatohepatitis can be reversed after timely intervention. If 
not, steatohepatitis can progress to advanced cirrhosis, which is associated with a high risk 
of HCC (2).  
Liver is one of the important organs in regulation of glucose and lipid metabolism, and 
the dysfunction of glucose and lipid metabolism are fundamental in development and 
progression of NAFLD. The homeostasis of lipid metabolism includes lipid input and 
output in liver (Figure 1.1). On the input side, lipids can be taken up via the blood stream 
in the form of chylomicrons (CM) from dietary fat ingestion and free fatty acids derived 
mainly from lipolysis. Lipids may be synthesized (de novo) from carbohydrates or other 
precursors. The key proteins involved in influx of fatty acid in liver include fatty acid 
transport proteins (FATPs), plasma membrane fatty acid binding protein (FABP) and fatty 
acid translocase (CD36/FAT), which are associated with hepatic steatosis (3-5). The key 
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enzymes involved in de novo lipogenesis are ATP-citrate lyase (Acly), acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (Fasn) (6). Moreover, the transcription factors, 
such as liver X receptor (LXR), sterol regulatory element-binding protein-1c (SREBP-1c), 
and carbohydrate response element binding protein (ChREBP) also control de novo 
lipogenesis (7, 8). Free fatty acids are mainly used to synthesize triglycerides and are stored 
in hepatocytes. On the output side, lipids can be secreted into blood in lipoprotein form, 
such as very-low-density-lipoprotein (VLDL) by interaction with apolipoproteinB-100 
(ApoB-100) (8), and be utilized in mitochondria (fatty acid oxidation) as an energy source 
to produce ATP (9). In the normal physiological status, the liver total lipids input equals 
the total lipids output. However, once the total lipids input rate exceeds output rate, 
excessive lipids would be ectopic deposited, resulting in hepatic steatosis. Therefore, the 
factors that disturb the balance of lipid metabolism will induce NAFLD. 
 
 
Figure 1.1 The homeostasis of liver lipid metabolism. Figure adapted from Jonathan C. 
Cohen et al., Science, 2011; 332:6037 
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The prevalence of NAFLD parallels the incidence of obesity and type 2 diabetes 
(T2DM). With the increasing incidence of obesity and T2DM, NAFLD is the most 
prevalent liver disease with a global prevalence estimate of 24 %, with the highest rates of 
NAFLD in South America (31 %) and the Middle East (32 %), followed by Asia (27 %), 
the USA (24%) and Europe (23 %), and lowest in Africa (14 %) (10, 11). The prevalence 
of NAFLD across geographical locales is shown in Figure 1.2 based on community surveys 
(11). Not all subjects with obesity develop NAFLD; and not all subjects with steatosis 
develop progressive liver disease. Seventy to eighty percent of obese and diabetic 
individuals develop NAFLD, 5-10 % subject with steatosis develop NASH, and 30 % of 
patients with NASH develop cirrhosis. Among patients diagnosed with cirrhosis, only 1-
2 % of patients progress to HCC within 10 years of developing cirrhosis (12). The 
pathogenesis of NAFLD development, and progression to advanced fatty liver disease is 
not completely understood. Generally, the interaction of lifestyle (13), nutrients (14) and 
genetics (15) affect the pathogenesis of NAFLD/NASH. The potential molecular 
mechanisms include insulin resistance, lipotoxicity, mitochondrial oxidative stress, ER 
stress, disrupted adipokines, inflammatory cytokines, autophagy, and changes in gut 
microbiome (16-18). Several susceptibility genes for NAFLD development have been 
identified, such as patatin-like phospholipase domain-containing-3 (PNPLA3). The 
PNPLA3 (rs738409) polymorphism genotype distribution corelated with worldwide 






Figure 1.2 The global estimated prevalence of NAFLD and PNPLA3 rs738409 genotype 
distribution. Figure adapted from Younossi et al., Nature Reviews Gastroenterology & 
Hepatology, 2017;15:11. 
 
NAFLD is associated with abnormal level of blood lipids that increase mortality from 
liver and cardiovascular disease. Indeed, hypertriglyceridemia is the metabolic 
comorbidity most frequently associated with NAFLD. For patients with end stage liver 
disease, and cirrhosis, liver transplantation is the major strategy to rescue them. Thus, 
NAFLD is a heavy burden on public health globally. In the USA, it is estimated annual 
direct medical costs for NAFLD are about $103 billion (21). To date, there are no FDA-
approved drugs for NAFLD/NASH treatment, and lifestyle improvements, such as body 
weight loss and physical exercise, are the only ways to improve NAFLD/NASH (22). 
However, experimental therapies involve targeting hepatic fat accumulation, anti-oxidants, 
anti-inflammation, anti-apoptosis, gut microbiome and anti-fibrotic (23, 24). Among these 
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developed chemicals, dual peroxisome proliferator-activator receptor α/δ agonist 
(elafibranor) (25, 26), farnesoid X receptor agonist (obeticholic acid) (27, 28), apoptosis 
signaling kinase 1 (ASK1) inhibitor (29, 30), and cysteine–cysteine motif chemokine 
receptor-2/5 antagonist (cenicriviroc) (31, 32), are being evaluated in phase III trial for 
NAFLD/NASH .  
The “two-hit” hypothesis of NAFLD/NASH has been proposed (33), but this view has 
been challenged by “multiple parallel hits” hypothesis based on recent new findings (34). 
In the “two-hit” hypothesis, fat accumulation serves as the first hit, and increases 
susceptibility to subsequent second hits, which are responsible for liver injury, 
inflammatory cell infiltration and hepatic fibrosis. Occupational and environmental 
chemicals are another category of second hit. The terms toxicant-associated fatty liver 
disease (TAFLD) and/or toxicant-associated steatohepatitis (TASH) have been proposed 
to describe this condition(35). The TASH was firstly described in non-obese vinyl chloride 
(VC) workers, which is characterized by the presence of necrotic cell death, as indicated 
by elevated total cytokeratin 18, elevated proinflammatory cytokines, impaired insulin 
sensitivity and antioxidant defenses, but with normal serum transaminases levels. Selected 
pollutants associated with TAFLD/TASH in human and animal studies have been reviewed 
(36, 37). Since the similar histopathology exists among NAFLD/NASH and 
TAFLD/TASH, the distinction between them will not be made in the following text.  
2. Polychlorinated biphenyls  
Polychlorinated biphenyls (PCBs) are thermodynamically stable polyhalogenated 
aromatic hydrocarbons consisting of up to ten chlorine substituents attached to biphenyl 
rings (Figure 1.3). There are 209 different congeners, defined by the number and position 
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of chlorines attached to the biphenyl rings. Due to their thermodynamic stability and 
excellent electrical insulation and heat transfer properties, PCBs were widely used as 
insulating fluids in electrical transformers and capacitors. A total of 1.3 million tons of 
PCB mixtures were produced for a variety of commercial applications before PCBs were 
banned. PCB production was banned by the United States Congress in the later 1970’s and 
globally by the Stockholm Convention in 2001 (38). 
 
                      
 
Figure 1.3 Chemical structure of PCBs. PCBs have the basic chemical formula (C12H10-
nCln), where n means the number of chlorine atoms, and number means the positions 
where a chlorine atom is attached to biphenyl rings.  
 
Although PCBs production was banned for more than 30 years, PCBs still exist in the 
environment due to their higher thermostability, and resistant to degradation by the 
microbes, thus, PCBs belong to a category of “persistent organic pollutants” (POPs), and 
are widely dispersed in the global ecosystem, including water, soil, air, aquatic wildlife and 
mammals (39, 40). Highly chlorinated PCBs have bioaccumulated and are detected in 
human adipose tissues, liver, serum, and milk due to low metabolic degradation rate (41-
43). Currently, inadvertent PCB production still occurs (44) and PCBs exposure occur 
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mainly through inhalation of contaminated indoor air (45) and contaminated food 
consumption (46). 
The chlorination pattern of the PCBs is important for the toxicity of these congeners. 
PCB congeners have been subclassified into two major categories:  coplanar and non-
coplanar PCBs. Coplanar PCB congeners have none or only one chlorine atom attach to 
the ortho-position of biphenyl rings, known as non-ortho and mono-ortho PCBs, 
respectively. There are total 12 coplanar PCBs. Non-ortho PCBs include PCB 77, PCB 81, 
PCB 126, and PCB 169, and the rest of them are mono-ortho PCBs, such as PCB 114 and 
PCB 189, etc (Figure 1.4). Coplanar PCBs exhibit dioxin-like toxicity, and are also known 
as dioxin-like (DL) PCBs. Non-coplanar PCB congeners have two or more chlorine atoms 
at the ortho-position of biphenyl rings, and do not resulted in dioxin-like properties, thus, 
they are known as non-dioxin-like (NDL) PCBs.  
The DL-PCB congeners interact with aryl hydrocarbon receptor (AhR), which may 
mediate their toxic effects. Among 12 DL-PCB congeners, PCB 126 exhibits the highest 
AhR binding affinity, and is the potent congener of DL-PCBs. Therefore, PCB 126 was 
selected for the proposed studies. Animal studies have shown that the toxic effects of PCB 
126 include developmental toxicity (47), hepatic toxicity (48), reproductive toxicity (49), 
and neurological toxicity (50). The unfavorable effects of PCB 126 may be also mediated 
by interaction with other receptors, such as estrogen receptor (ER) (51). On the other hand, 
the toxicologic mode of action of NDL-PCBs, has been attributed to interactions with a 
variety of other cellular receptors, including pregnane X receptor (PXR) and constitutive 
androstane receptor (CAR) (52), as well as, ER, androgen receptor, and thyroid receptor 






Figure 1.4 Chemical structure of DL-PCB congeners. The DL-PCBs in left column are 
non-ortho PCBs, and the rest of them are mono-ortho PCBs. Figure adapted from website: 
https://en.wikipedia.org/wiki/Polychlorinated_biphenyl 
 
The liver is the major organ for PCB metabolism via phase I (cytochrome P450 
enzymes) and phase II (conjugation pathways) pathways to convert them to water soluble 
metabolites, and remove them from body. The detailed metabolic pathways of PCBs bio-
transformation are well summarized and reviewed (54). The rate and extent of PCB 
metabolism depends on the numbers and position of chlorines in the biphenyl rings. 
Generally, the lower the number of chlorines on the biphenyl rings, the faster the 
metabolism. Therefore, highly chlorinated PCBs tend to be bio-accumulated and detected 
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in human fat tissues or in plasma due to their lipophilic properties (55). In fact, the median 
concentration of the sum of 35 PCB congeners (ΣPCBs) was 528 ng/g lipid in participants 
of the Anniston Community Health Survey (ACHS) (55), and ACHS participants have 
serum concentrations of ΣPCBs two to three times higher than those in comparable age and 
race groups from National Health and Nutrition Examination Survey (NHANES) 2003–
2004 sample of the general United States population (56). 
Commercial PCBs were made and used in mixtures rather than individual congeners. 
In the United States, commercial PCB mixtures were produced by the Monsanto Company 
and marketed under the trade names Aroclor. Manufacturing plants included Anniston, 
Alabama. There are different types of Aroclor mixtures and each of them has a 
distinguishing suffix number that indicates the degree of chlorination. The first two 
numbers usually mean the total number of carbon atoms in biphenyl rings and the last two 
digits refer to the percentage of chlorines by mass in the mixture. Commercial PCB 
mixtures were also made globally, and marketed under different trade names. ACHS study 
demonstrated that higher incidences of hypertension, obesity, diabetes and liver disease 
was positively correlated to PCBs load in residents (57, 58).  
Aroclor 1260, one of the commercial PCB mixtures in North America, contains sixty 
percent chlorine atoms by mass. The PCB congeners of Aroclor 1260 usually are highly 
chlorinated congeners with more than 5 chlorine substituents. As lowly chlorinated PCB 
congeners are easily metabolized and eliminated, only highly chlorinated PCB congeners 
are resistant to metabolism, and have bio-accumulated in humans. Our previous study 
demonstrated that the PCB profiles in Aroclor 1260 best mimic the PCBs present in human 
adipose tissue (52) (Figure 1.5). However, Aroclor 1260 contains lower amounts of DL-
10 
 
PCB congeners.  A 20 mg/kg exposure of Aroclor 1260 did not activate AhR in mice (52, 
59). The less chlorinated PCB mixtures were also made by Monsanto Company with 




Figure 1.5 Relative PCB composition in human adipose tissue and Aroclor 1260. Figure 
adapted from Wahlang, et al., Toxicol Sci, 2014,140 (2): 283-297. 
 
Two major human PCB exposure events occurred in Japan (known as “Yusho”) in 
1968 (60) and in Taiwan (known as “Yucheng”) in 1978 (61), both as results of 
contaminated rice oil consumption. In Yusho, maternal exposed women tend to give 
offspring with lower birth weight (62). Follow-up studies of the Yucheng events have 
demonstrated neurocognitive deficits in elderly women patients (63) and increased 
mortality from chronic liver disease and cirrhosis in men (64, 65). Moreover, multiple 
epidemiological studies have reported associations between PCB exposure and suspected 
steatohepatitis (42)  and/or diabetes (57, 66) in NHANES and ACHS studies.  
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As liver is the major site of PCB metabolism, and the lower chlorinated metabolites 
could adduct to DNA, proteins and lipids, and associate with activation of various hepatic 
receptors; thus, liver is the major target organ for the toxic effects of PCBs exposure. The 
nutrient-PCB interaction also affects PCB toxicity in liver. For example, DL-PCBs interact 
with AhR, and induce NAFLD in normal diet, while NDL-PCBs mixture interact with 
nuclear receptors, and exacerbate high fat diet-induced injury, leading to NASH. Therefore, 
PCBs have also been classified as endocrine and metabolism disrupting chemicals 
(EDCs/MDCs). EDCs interfere with any aspect of hormone action, resulting in endocrine 
dysfunction; while MDCs promote metabolic changes, resulting in metabolic disease (66).  
3. Xenobiotic receptors 
The functions of xenobiotic receptors are not only related to chemical detoxification, 
but also contribute to glucose and lipid metabolism, which are associated with metabolic 
disease, including NAFLD/NASH. In the current dissertation, the xenobiotic receptors of 
aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane x 
receptor (PXR) will be discussed.  
 The AhR is a ligand-binding activated transcription factor that belongs to the Per-
Arnt-Sim family. The molecular mechanisms of AhR activation have previously been 
reviewed (67) (Figure 1.6). Unliganded AhR resides in cytoplasm of cells, forming a 
protein complex with a heat shock protein 90 (HSP90) dimer and the co-chaperone protein 
X-associated protein 2 (XAP2), collectively they retard AhR translocation to nucleus. 
Upon binding an agonist, the AhR complex translocates to the nucleus and AhR nuclear 
translocator (ARNT) mediates HSP90 displacement, leading to AhR-ARNT heterodimer 
formation. This dimer is capable of binding to a dioxin-responsive element (DRE), thereby 
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regulating the transcription of many genes, such as the cytochrome P4501A (CYP1A) 
family. Cypa1a1 and Cyp1a2, are the major members of Cyp1a family that metabolize the 
pro-carcinogenic chemicals to their carcinogenic form, which react with DNA to form 
mutagenic adducts, resulting in carcinogenesis. The high-affinity binding agonists for AhR 
are often xenobiotics, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2-
benzo[a]pyrene (BA) and DL-PCBs. Moreover, low-affinity binding agonists for AhR 
have been discovered in diet (flavonoids and indoles), endogenously as bilirubin and 
tryptophan metabolites, and as products of the microflora (67, 68). On the other hand, 
ligand-independent indirect activation of AhR has been reported, such as that seen with 
omeprazole (69).  
Associated with regulation of physiological functions, such as innate and adaptive 
immune responses (68), AhR activation also is involved in the processes of glucose and 
lipid metabolism. Pharmacologic activation of AhR (70) or constitutively activated AhR 
(71) induces hepatic steatosis via upregulation of fatty acid transport genes, such as 
CD36/FAT. Alteration of hepatic fatty acid composition (72) and decreased fatty acid 
oxidation (73) contribute to AhR ligand-induced liver toxicity and steatosis. On the 
contrary, AhR deficiency protects against high fat diet-induced obesity, improves insulin 
sensitivity, and attenuates hepatic steatosis (74, 75). Interestingly, liver-specific AhR 
knockout mice are prone to HFD-induced hepatic steatosis, inflammation and injury (76), 
suggesting AhR activation protects against fatty liver disease. Moreover, a disassociation 
of hepatic steatosis and insulin resistance has been found in constitutively activated AhR 
mice (77) by inducing a novel AhR target gene, fibroblast growth factor 21 (FGF21) (78). 
Moreover, TCDD or PCB 126 exposure-induced AhR activation suppresses hepatic 
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gluconeogenesis by inhibition of gluconeogenic gene expression, such as phosphoenol-




Figure 1.6 Scheme of AhR activation by agonist binding. Figure are adapted from 
Murray et al., Nat Rev Cancer, 2015, 14 (12): 801-814. 
 
PXR (nuclear receptor subfamily 1, group I, member 2, NR1I2) and CAR (nuclear 
receptor subfamily 1, group I, member 3, NR1I3) are members of the orphan nuclear 
receptor subclass. The major functions of these receptors are regulating transformation and 
elimination of chemicals in liver by regulation of phase I and phase II drug metabolizing 
enzymes and drug transporters (81). The direct and indirect molecular mechanisms of CAR 
and PXR activation have been reviewed (82). A variety of structurally related PXR and 
CAR ligands has been reported, including drugs, environmental pollutants, and endobiotics. 
Moreover, specific ligands diversity and species diversity are well known. For example, 
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the CAR ligands for human and mouse are 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-
5-carbaldehydeO-(3,4dichlorobenzyl)oxime (CITCO) and 1,4-bis[2-(3,5-dichloropyridyl- 
oxy)]benzene (TCPOBOP), respectively. Activation of PXR induces expression of target 
genes of the Cyp3a family, including Cyp3a11 in mice and Cyp3a4 in human, while CAR 
target genes of the Cyp2b family, such as Cyp2b10 in mice and Cyp2b6 in human, are 
induced upon activation. PXR and CAR are sister xenobiotic receptors as they regulate 
many overlapping genes involved in chemical and drug detoxification and transportation.  
 Similar to AhR, PXR and CAR activities also are involved in metabolic disease by 
modulating glucose, fatty acid, and lipid metabolism directly or indirectly (81, 83, 84). 
CAR activation increases insulin sensitivity, improves type 2 diabetes and fatty liver 
disease (85, 86). Moreover, TCPOBOP treatment attenuates methionine choline-deficient 
(MCD) diet- induced NASH (87). The role of PXR activation in obesity is controversial, 
as ligand-induced PXR activation protects against high fat diet-induced obesity (88), while 
PXR ablation alleviates high fat diet-induced or genetic obesity, and improves insulin 
sensitivity (89). Activation of either PXR or CAR suppresses hepatic gluconeogenic gene 
expression by inhibition of transcriptional factors such as forkhead box protein O1 (FoxO1), 
hepatocyte nuclear factor 4 alpha (HNF4a), and peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC1a) (90, 91). Furthermore, PXR activation suppresses 
inflammation and is a promising target for inflammatory diseases (92).  
The detoxification of PCBs is associated with nuclear receptor CAR and PXR 
activation, and in turn, CAR and PXR activation affect PCBs exposure-induced metabolic 
disorders. Our previously published data suggest Aroclor1260, a NDL-PCB congeners 
mixture, activates human PXR and CAR3 variant, and is a mixed agonist/antagonist for 
15 
 
the human CAR2 variant based on cell culture model (52). In vivo, Aroclor 1260 treatments 
activate CAR and PXR, as evidenced by induced expression of their target genes, Cyp2b10 
and Cyp3a11 at low doses, Aroclor 1260induced expression of AhR target gene Cyp1a2 
requires much higher doses due to the low amounts of DL-PCBs (59). Moreover, Aroclor 
1260 treatments promote hepatic steatosis progression to steatohepatitis only at low dose, 
but not at high dose, under high fat diet conditions.  PCB congeners apparently do not 
directly bind with the CAR, and the potential indirect mechanism of activation of CAR by 
Aroclor 1260 exposure may be EGFR signaling inhibition (93, 94), this similar to the 
molecular mechanisms that was shown by the CAR indirect activator, phenobarbital (95).   
4. Aims and significance of current study 
Although animal exposure models have typically investigated the toxic effects of only 
single PCB congeners or NDL-PCBs mixture treatments, humans are simultaneously 
exposed to mixtures of DL- and NDL-PCB congeners. Because the DL- and NDL-PCBs 
have different toxicological mechanisms of action, exposures to both types of PCBs might 
be synergistic or not. Therefore, the aims of the current dissertation are to investigate and 
compare DL-PCB congener (PCB 126), NDL-PCBs mixture (Aroclor 1260), and 
DL/NDL-PCBs mixture (Aroclor 1260 plus PCB 126) exposure related NAFLD/NASH 
and metabolic dysfunction. The potential role of AhR in PCB mixtures exposure-induced 
NAFLD/NASH will also be investigated.  
As aforementioned, Aroclor 1260 best mimics PCBs that are seen in human adipose 
tissue (52), and Aroclor 1260 exposure is considered to be a ‘second hit’ in the conversion 
of diet-induced hepatic steatosis to the more advanced steatohepatitis. However, Aroclor 
1260 (20 mg/kg) did not induce hepatic expression of prototypical AhR target genes (52, 
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59), because it did not contain a significant amount of DL-PCBs, such as PCB 126. To best 
mimic the DL/NDL-PCBs bioaccumulation pattern and the highest levels of exposure seen 
in humans (52), we added a small quantity of DL-PCB 126 which represents approximately 
0.02% of human total PCBs exposure based on NHANES data. Because PCB 126 is not 
the only DL-PCB congener extant, and human exposures vary, the PCB 126 dose was 
increased to 0.1% (20 µg/kg).    
The specific aims of my dissertation are shown as follows. 
Specific Aim 1 will address whether DL-PCBs, NDL-PCBs, and DL/NDL-PCBs act 
differently on fatty liver disease. We will use male C57BL/6 mice on control synthetic diet 
to ascertain whether single treatment with Aroclor 1260, PCB 126, or Aroclor 1260/0.1% 
PCB 126 for 2 weeks activate AhR and downstream target genes, and lead to steatosis and 
liver injury (inflammatory markers, steatosis markers, and lipid metabolism markers). Next, 
male wild type C57BL/6 mice fed fat diet received the same PCB treatments for 12 weeks. 
The animals will be sacrificed and the liver mRNA levels of disease markers (receptors 
and their downstream targets, inflammatory markers, markers of fat metabolism), and 
pathological changes will be measured, to ascertain whether AhR is essential for PCBs-
induced liver disease.  
Specific Aim 2 will address whether human and murine AhR display the same 
concentration-dependence for ligand activation in response to PCBs. Initially, we will use 
cultured human (HepG2) and murine (Hepa1c1c7) hepatoma cells transfected with a XRE-
Luc reporter to determine the relative affinity of the mixture Aroclor 1260, Aroclor 1254, 
selected DL-PCB congeners, including PCB 126, PCB 77, PCB 114, and PCB 81, and a 
mixture of DL/NDL-PCBs mixture (Aroclor 1260 plus 0.1% PCB 126, Ar1260/PCB 126). 
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This allows us to ascertain if the murine and human AhR are equally sensitive to PCB 
ligands or if the murine AhR binds ligands with higher affinity than the human receptor. 
We subsequently used murine and human primary hepatocytes to further test this 
hypothesis in an in vitro model. This aim is important for reverse translation studies 




ACUTE POLYCHLORINATED BIPHENYL TREATMENTS REGULATE HEPATIC 
METABOLISM AND PANCREATIC FUNCTION: IMPLICATION FOR NON-
ALCOHOLIC FATTY LIVER DISEASE AND DIABETES 
1. Introduction 
The commercially manufactured PCBs mixture that best mimics human PCB (by mass) 
bioaccumulations patterns in adipose tissue is Aroclor 1260, which is a NDL-PCBs mixture 
(52). Aroclor 1260 is considered a ‘second hit’ in the conversion of diet-induced hepatic 
steatosis, to the more advanced steatohepatitis. It also decreased pancreatic insulin 
production (59). However, low doses of Aroclor 1260 (20 mg/kg) did not induce hepatic 
expression of prototypical AhR target genes (52, 59), because it should not contain a 
significant amount of DL-PCBs, such as PCB 126, as indicated by high doses of Aroclor 
1260 (200 mg/kg) required to observe AhR activation. Therefore, a high dose of PCB 126 
was used to evaluate the toxic effects on fatty liver disease (48, 96, 97). 
While humans are simultaneously exposed to mixtures of DL- and NDL-PCBs, animal 
exposure models have typically investigated the effects of only a single congener or NDL-
PCBs mixture as mentioned before. Because the DL- and NDL-PCBs have different 
toxicological mechanisms of action, DL/NDL-PCBs mixture exposures to both types of 
PCBs might be synergistic. In PCB mixtures and especially among bioaccumulated PCBs, 
DL-PCBs are minor constituents. Using NHANES data, PCB 126 represents 
approximately 0.02 % of the total PCB load in human serum (98).
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The purpose of this subacute exposure study was to perform an integrated analysis of 
liver, pancreas, and serologic endpoints using exposures that better mimic high level 
human exposures to examine if the rodent AhR is activated and if mixtures of DL- and 
NDL-PCBs will behave like DL- or NDL-PCBs alone. My hypothesis is that at the highest 
human levels of exposure observed in literature, the rodent AhR will be activated, but that 
mixtures of DL- and NDL-PCBs will act differently. The mice were fed a control synthetic 
diet and exposed to: a low-dose of a DL-PCB congener (PCB 126, 20 µg/kg), an NDL-
PCB mixture (Aroclor 1260, 20 mg/kg), an environmentally relevant mixture of low-dose 
PCB 126 (20 µg/kg) plus Aroclor 1260 (20 mg/kg); or vehicle. The possible impact of 
PCBs on novel mechanisms of endocrine and metabolic disruption [e.g., novel hepatokines 
(99) and genes regulating pancreatic islet cell identity and function (100)] will be 
investigated. This study could inform the direction of subsequent studies of combined 













2. Materials and Methods 
Reagents 
Aroclor 1260 and PCB 126 were purchased from AccuStandard, Inc., (New Haven, 
CT). RNA-STAT 60 were ordered from Amsbio., (Austin, TX) and QuantiTect Reverse 
Transcription Kit were obtained from Qiagen, (Valencia, CA). iTaq Universal probes 
Supermix was supplied by Biorad, (Hercules, CA). Taqman probes for real-time 
polymerase chain reaction (RT-PCR) and Infinity TM Triglycerides were obtained from 
Thermo Fisher Scientific, Inc., (Middletown, VA). Free fatty acids test kits were purchased 
from Roche Dignostics, (Indianapolis, IN). Lipid panel plus kits were obtained from 
Abaxis, (Union City, CA). The customized Milliplex® MAP Panel was obtained from 
Millipore Corp, (Billerica, MA). The other reagents were obtained from Sigma-Aldrich, 
(St. Louis, MO). 
Animal exposures 
The animal protocol used was approved by the University of Louisville Institutional 
Animal Care and Use Committee. Male C57BL/6j mice (10 weeks old) were obtained from 
The Jackson Laboratory (Bar Harbor, ME), and divided into 4 groups (n=10) based on the 
different exposures. All the mice were fed a control synthetic diet (20.0 %, 69.8 %, and 
10.2 % of total calories come from protein, carbohydrate, and fat, TekLab TD06416). Mice 
were treated by one-time gavage with either Aroclor 1260 (20 mg/kg), PCB 126 (20 µg/kg), 
Aroclor 1260 (20 mg/kg) with 0.1 % PCB 126 (20 µg/kg) or vehicle control (corn oil) for 
2 weeks. Mice were housed in a temperature- and light controlled-room (12 h light; 12 h 
dark) with food and water ad libitum. The animals were euthanized at the end of week 2 
using ketamine/xylazine (100/20 mg/kg body weight, i.p.) and the blood, liver, pancreas, 
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and fat tissues were collected. Dual energy X-ray absorptiometry (DEXA) scanning (Lunar 
PIXImus densitometer, WI) was performed to analyze body fat composition prior to 
euthanasia. 
Histological staining 
The liver and pancreas tissues were fixed in 10 % neutral buffered formalin for 72 
hours and embedded in paraffin for routine histological examination. Hematoxylin–eosin 
(H&E) staining were performed to observe histopathological changes. Photomicrographic 
images were acquired using a high-resolution Olympus digital scanner on an Olympus 
digital camera (BX41).  
Real-time PCR 
The liver and pancreas tissues were homogenized and total RNA was extracted using 
RNA-STAT 60 according to the manufacture’s protocol. The purity and quantity of total 
RNA were assessed with Nanodrop spectromer (ND-1000, Thermo Fisher Scientific, 
Wilmington, DE) using ND-1000 V3.8.1 software. cDNA was synthesized using the 
QuantiTect Reverse Transcription Kit according to the manufacture’s protocol. RT-PCR 
was performed on the CFX384 TM Real-Time System (Biorad, Hercules, CA) using iTaq 
Universal probes Supermix and Taqman probes. The probes sequence were as follows: 
mouse AhR (Mm00478932_m1); mouse CAR (Nr1i3) (Mm01283978_m1); mouse PXR 
(Nr1i2) (Mm01344139_m1); cytochrome P450s, including Cyp1a2 (Mm00487224_m1), 
Cyp2b10 (Mm01972453_s1), Cyp3a11 (Mm00731567_m1), and Cyp4a10 
(Mm02601690_gH); carnitine palmitoyl transferase 1A (Cpt1α) (Mm01231183_m1); 
peroxisome proliferator-activated receptor alpha (Pparα) (Mm00440939_m1); Cd36 
(Mm01135198_m1); fatty acid-binding protein 1 (Fabp1) (Mm00444340_m1); fatty acid 
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synthase (Fasn) (Mm00662319_m1);  stearoyl coenzyme A desaturase1 (Scd1) 
(Mm00772290_m1); Pnpla3 (Mm00504420_m1); fibroblast growth factor 21 (Fgf21) 
(Mm00840165_g1); insulin-like growth factor 1 (Igf1) (Mm00439560_m1); betatrophin 
(Mm01175863_g1), glucose 6-phosphate (G6P) (Mm00839363_m1); 
phosphoenolpyruvate carboxy kinase (Pck1) (Mm01247058_m1); insulin 
1(Mm01950294_s1); Nkx6-1 (Mm00454961_m1); NR4a1 (Mm01300401_m1); NR4a3 
(Mm00450071_g1); pancreatic polypeptide (Mm00435889_m1); and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Mm99999915_g1). All reactions were run in 
triplicate. The relative expression of each mRNA was calculated using the comparative 2-
△△Ct method and was normalized against GAPDH mRNA.  
Measurement of hepatic lipid 
The liver tissues were rinsed in neutral 1× phosphate buffered saline (PBS) and 
homogenized in 50 mM NaCl solution. Hepatic lipids were extracted by a mixed solution 
of chloroform and methanol (2:1) according to a published protocol (101). Total lipid 
extracts were dried using nitrogen before they were dissolved in PBS containing 1 % triton 
X-100. Hepatic triglycerides and free fatty acid contents were measured using commercial 
kits and normalized to liver weight. 
Measurement of plasma lipid and cytokine 
Blood samples were collected by syringe with anti-coagulated EDTA. Plasma was 
obtained after centrifugation at 3,000 rpm for 20 min at 4 ℃ . Plasma ALT, AST, 
triglyceride, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDH), 
very low-density lipoprotein (VLDL), and non-HDL cholesterol (nHDLc) levels were 
measured by Piccolo Xpress Chemistry Analyzer using the lipid panel plus kits. Plasma 
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cytokine and adipokine levels were measured on a Luminex® 100 system using a 
customized Milliplex® MAP mouse adipokine Panel.  
Statistical analysis 
Statistical analyses were carried out using SigmaPlot 11.0 software (Systat Software 
Inc., San Jose, CA). Data are presented as mean ± SEM. Statistical evaluation of the data 
was performed using two-way analysis of variance (ANOVA). Fold-changes are fold of 
vehicle control group. For all statistical comparisons, p-values less than 0.05 were 



















Effects of PCB exposures on body weight and composition 
There were no significant changes in body weight in either group (Fig. 2.1 A). 
Regarding body composition, there were no significant trends towards increased percent 
body fat with Aroclor 1260 (14.0 %) or PCB 126 (7.5 %). The interaction between Aroclor 
1260 and PCB 126 significantly decreased percent body fat in the DL/NDL-PCBs mixture-
treated group compared to either alone exposure (Fig. 2.1 B). No significant changes were 
observed in the liver/body weight ratio (Fig. 2.1 C) or the epididymal fat/body weight ratio 
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Figure 2.1 Effects of PCB exposures on liver and fat weight. (A) The body weight, (B) 
body fat composition, (C) the ratio of liver weight to body weight, (D) the ratio of 
epididymal fat weight to body weight. Data are presented as mean ± SEM. n=10. p<0.05, 










Effects of PCB exposures on hepatic expression of AhR, CAR, PXR, and their target genes 
To determine if PCB exposures affected mRNA expression of hepatic xenobiotic 
receptors (AhR, CAR, PXR) and their target genes, hepatic mRNA expression was 
measured by RT-PCR. AhR mRNA expression was significantly decreased by either 
Aroclor 1260 (3.3-fold) or PCB 126 (3.2-fold) exposure, while the Aroclor 1260/ PCB 126 
mixture significantly increased AhR mRNA expression compared to either exposure alone 
(Fig. 2.2 A). PCB 126 alone (8.7-fold) or the Aroclor 1260/PCB 126 mixture (7.9-fold) 
activated AhR, as indicated by increased AhR target gene Cyp1a2 mRNA expression. The 
latter data suggest that the observed changes in the AhR mRNA expression levels did not 
affect its transcriptional activity (Fig. 2.2 B). CAR mRNA expression was slightly 
increased by PCB 126 alone or by the Aroclor 1260/PCB 126 mixture, but was not changed 
by Aroclor 1260 (Fig. 2.2 C). The CAR target gene Cyp2b10 mRNA expression was 
robustly increased by Aroclor 1260 (130,000-fold), while PCB 126 induced Cyp2b10 
mRNA expression to a much lower degree (25.0-fold). An interaction between Aroclor 
1260 and PCB 126 resulted in significantly different Cyp2b10 mRNA levels that were 
intermediate between either exposure alone (50,000-fold) (Fig. 2.2 D). PXR mRNA 
expression was significantly decreased by either Aroclor 1260 or PCB 126 exposures, but 
was increased by the Aroclor 1260/PCB 126 mixture compared to either exposure alone 
(Fig. 2.2 E). PXR-dependent gene Cyp3a11 mRNA expression was increased by Aroclor 
1260 (2.0-fold), and exposure with the Aroclor 1260/PCB 126 mixture attenuated this 
effect (Fig. 2.2 F). These results demonstrate that PCB 126 alone or in the DL/NDL-PCBs 
mixture activated AhR, and Aroclor 1260 potently activated CAR and to a lesser degree 
PXR. The PCB exposures differentially regulated AhR and nuclear receptor expression. 
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Moreover, the results suggested that PCB 126 activated AhR may suppress the activation 
of CAR and PXR by Aroclor 1260. However, the reciprocal effect of activating either CAR 
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Figure 2.2 Effects of PCB exposures on levels of hepatic AhR, CAR, PXR, and their target 
genes expression. Hepatic mRNA levels of AhR (A) and target gene Cyp1a2 (B), CAR (C) 
and target gene Cyp2b10 (D), PXR (E) and target gene Cyp3a11 (F) were measured by 
performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 
effects, b= PCB 126 effects; c= interaction between Aroclor 1260 and PCB 126. 
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Effects of PCB exposures on hepatic lipids 
To evaluate for hepatic steatosis, histologic staining (H&E) of liver was performed. 
PCB 126, but not Aroclor 1260 exposure, induced mild small droplet-macrovesicular 
steatosis. PCB 126-induced hepatic steatosis was attenuated in the DL/NDL-PCBs mixture 
(Fig. 2.3 A). These histologic steatosis results were confirmed by biochemical lipid assays. 
The hepatic triglyceride levels (30.7 %) (Fig. 2.3 B) and free fatty acid levels 
(approximately 60.0 %) (Fig. 2.3 C) were increased by PCB 126 exposure, but exposure 
with the mixture of Aroclor 1260 plus PCB 126 abrogated this affect. Aroclor 1260 
exposure had no effect on either hepatic triglycerides or free fatty acids (Fig. 2.3 B&C). 
Significant hepatic necroinflammation was not observed under any exposure in histology 
(Fig. 2.3 A); plasma alanine or aspartate aminotransferase levels (Fig. 2.3 D&E); or serum 
pro-inflammatory cytokines (IL-6, MCP-1, PAI-1) were not significantly altered within 
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Figure 2.3 Effects of PCB exposures on hepatic lipids. (A) H&E staining of liver, (B) 
hepatic triglycerides levels, (C) hepatic free fatty acid levels, plasma levels of (D) ALT, 
(E) AST, (F) IL6, (G) MCP1, and (H) PAI1. n=10. Data are presented as mean ± SEM. 
















Effects of PCB exposures on plasma lipids 
The PCB exposures had very different effects on plasma lipids. While PCB 126 
increased hepatic lipids, it significantly decreased plasma triglycerides, total cholesterol, 
HDL, VLDL, and nHDLc cholesterol (Fig. 2.4 A-E). Blood lipids were not affected by 
Aroclor 1260 either alone or in the DL/NDL-PCBs mixture. In summary, these data 
suggested that subacute, low-dose PCB 126 exposure caused toxicant-associated fatty liver 
disease (steatosis) without significant necroinflammation. The fatty liver disease was 
associated with a paradoxical decrease in blood lipids. Aroclor 1260 in the DL/NDL-PCBs 
mixture abrogated PCB 126-induced changes in liver, but not the blood lipid profile.  
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Figure 2.4 Effects of PCB exposures on plasma lipid levels. (A) Plasma triglyceride, (B) 
cholesterol, (C) high-density lipoprotein (HDL), (D) very low-density lipoprotein (VLDL), 
and (E) non-HDL cholesterol (nHDLc) levels were measured by Piccolo Xpress chemical 
analyzer (n=8-10). Data are presented as mean ± SEM. p<0.05, b= PCB 126 effects. 
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Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression 
Since PCB 126 exposure impacted liver and blood lipid levels, expression of lipid 
oxidation genes (PPARα and its targets, Cyp4a10 and Cpt1α) were measured. There was a 
trend towards increased Pparα mRNA expression by both PCB 126 and Aroclor 1260, but 
the mixture of both PCB types significantly decreased Pparα mRNA expression compared 
to either alone (Fig. 2.5 A). Both mRNA levels of Cpt1α (1.5-fold, Fig. 2.5 B) and Cyp4a10 
(1.2-fold, Fig. 2.5 C) were significantly increased by PCB 126. Neither Cyp4a10 nor Cpt1α 
mRNA expression was changed by Aroclor 1260 exposure. However, the DL/NDL-PCBs 
mixture increased Cyp4a10 mRNA expression (Fig. 2.5 C), while decreasing Cpt1α mRNA 
expression (Fig. 2.5 B) compared to PCB 126 exposure alone. Thus, PCB 126 exposure 
activated PPARα to induce expression of genes implicated in hepatic fatty acid β-oxidation. 
While this may have contributed to the observed hypolipidemic effects of PCB 126, it 
cannot account for the increased hepatic lipid levels and steatosis observed with this 
exposure. Likewise, the decrease in hepatic PPARα and Cpt1α mRNA expression cannot 
account for the decreased hepatic steatosis observed when Aroclor 1260 was given along 
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Figure 2.5 Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression. 
Hepatic mRNA levels of Cyp4a10 (A), Cpt1α (B), and Pparα (C) were measured by 
performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 
















Effects of PCB exposures on other genes of hepatic lipid metabolism 
Because PCB 126 induced hepatic steatosis that could not be explained by a reduced 
β-oxidation, expression of other hepatic lipid metabolism genes was measured. These 
genes were involved in hepatic fatty acid import (Cd36 and Fabp1), synthesis (Fasn), 
desaturation (Scd1), and also included the lipase implicated in NAFLD, Pnpla3. Cd36 
mRNA levels were significantly induced by either PCB 126 (350.0-fold) or Aroclor 1260 
(300.0-fold) exposures, but surprisingly exposure to the Aroclor 1260/PCB 126 mixture 
attenuated these effects compared to either alone (Fig. 2.6 A). Likewise, either PCB 126 
(1.5-fold) or Aroclor 1260 (1.3-fold) exposures significantly increased the mRNA levels 
of lipid transporter Fabp1, but Aroclor 1260/PCB 126 co-administration reduced Fabp1 
expression compared to either exposure alone (Fig. 2.6 B). Interestingly, there was nearly 
the mirror image observed between Cd36/Fabp1 and Fasn mRNA expression. Fasn 
mRNA expression was significantly decreased by either Aroclor 1260 (3.3-fold) or PCB 
126 (5.0-fold) exposures, but was increased by the mixture of Aroclor 1260 plus PCB 126 
compared to either exposure alone (Fig. 2.6 C). Thus, mono-exposure to either PCB 126 
or Aroclor 1260 increased hepatic lipid uptake while decreasing lipid biosynthesis, but 
these effects were abrogated by exposure to the NDL/DL-PCBs mixture. Thus, the 
increased steatosis observed with PCB 126 exposure was most likely due to increased 
hepatic lipid uptake despite decreased de novo lipid biosynthesis and increased β-oxidation. 
Exposure with either Aroclor 1260 (1.4-fold), PCB 126 (1.7-fold), or Aroclor 1260/PCB 
126 (2.3-fold) resulted in significant down-regulation of Scd1 mRNA levels (Fig. 2.6 D). 
This should increase the relative abundance of saturated fatty acids compared to 
unsaturated fatty acids. A loss of function polymorphism in the hepatic lipase, PNPLA3, 
36 
 
results in the accumulation of mutant protein on lipid droplets to increase human NASH 
(102). Pnpla3 mRNA expression was significantly induced by Aroclor 1260 (3.0-fold) 
exposure, but was suppressed by either PCB 126 (2.3-fold) or Aroclor 1260/PCB 126 (7.7-
fold) exposure (Fig. 2.6 E). While the impact of these effects on steatohepatitis in rodents 
expressing wild type Pnpla3 may not impact the degree of steatosis, the induction of mutant 
human PNPLA3 by Aroclor 1260 is predicted to increase NASH, while the suppression of 
the mutant human PNPLA3 by the other exposures is predicted to be protective (102). 
Pnpla3 expression may be regulated by both CAR (103) and the  AhR (104). Our data 
suggested that there may be interaction between Aroclor 1260-activated CAR and PCB 
126-activated AhR effecting the expression of Pnpla3. In summary, while all PCB 
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Figure 2.6 Effects of PCB exposures on genes expression of hepatic lipid metabolism. 
Hepatic mRNA levels of Cd36 (A), Fabp1 (B), Fasn (C), Scd1 (D), and Pnpla3 (E) were 
measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= 










Effects of PCB exposures on hepatokine expression 
The liver also functions as an endocrine organ that plays a major role in the 
development of obesity, diabetes, and metabolic syndrome. Hepatic mRNA expression 
levels of several protective hepatokines previously implicated in these processes (e.g., 
Fgf21, Igf1, and betatrophin) were measured. The Fgf21 mRNA expression was 
significantly down-regulated by either Aroclor 1260 (10.0- fold) or PCB 126 (4.0-fold) 
exposure compared to control groups. In contrast, administration of Aroclor 1260/PCB 126 
mixture increased Fgf21 mRNA expression compared to either alone (Fig. 2.7 A). Hepatic 
Igf1 mRNA expression was significantly increased after exposure with either Aroclor 1260 
(1.2-fold) or PCB 126 (1.6-fold) compared to control groups, while Aroclor 1260/PCB 126 
mixture administration resulted in a reduction of Igf1 mRNA expression compared to either 
alone (Fig. 2.7 B). Although it is controversial whether betatrophin promotes islet β cells 
expansion (105, 106), the expression of betatrophin mRNA was affected by PCBs 
exposure. Aroclor 1260 exposure (2.1-fold) significantly induced betatrophin mRNA 
expression, but not by PCB 126 exposure. Mixture of PCB 126 of Aroclor 1260 abolished 
Aroclor 1260-induced betatrophin mRNA expression (Fig. 2.7 C). These results suggested 
that environmental PCBs exposure may disrupt the liver-pancreas axis, leading to the 
development of NAFLD/NASH and diabetes. In summary, Aroclor 1260 increased mRNA 
expression of Igf1 and betatrophin while decreasing mRNA expression of Fgf21. Addition 
of PCB 126 to Aroclor 1260 produced the opposite effects. PCB 126 exposure alone 
increased Igf1 and decreased Fgf21 mRNA expression. These results demonstrated that the 




    A                                            B                                            C 
   
 
Figure 2.7 Effects of PCB exposures on hepatokines expression. Hepatic mRNA levels of 
Fgf21 (A), Igf1 (B), and betatrophin (C) were measured by performing RT-PCR. Data are 
presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects, b= PCB 126 effects; c= 
















Effects of PCB exposures on pancreas structure 
Because PCB exposures have been associated with diabetes, the effects of the PCB 
exposures on the pancreatic structure were evaluated. The pancreas weight to body weight 
ratio was unaffected by either Aroclor 1260 or PCB 126 exposures (Fig. 2.8 A). However, 
it was significantly decreased (25.3 %) by Aroclor 1260 / PCB 126 co-exposure (Fig. 2.8 
A). H&E staining demonstrates pancreatic structural changes following exposure with the 
NDL/DL PCB mixture (Fig. 2.8 B). Specifically, this co-exposure was associated with 
pancreatic degeneration with acinar cell steatosis and atrophy occurring in the absence of 
ductal changes or inflammation. These changes did not occur with the other PCB exposures 
(Fig. 2.8 B). To further evaluate the pancreatic pathology associated with Aroclor 
1260/PCB 126 co-exposure, trichrome stain was performed. The co-exposed mice had 
mildly increased pancreatic fibrosis compared to mice treated with vehicle control (Fig. 
2.8 C).  
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Figure 2.8 Effects of PCB exposures on pancreatic structure.  (A) The ratio of pancreas 
weight to body weight, (B) H&E staining of pancreas (20 ×), and (C) trichrome staining 
(40 ×). Blank arrow indicates lipid droplet and blank star means degeneration in pancreas. 






Effect of PCB exposures on pancreatic function  
The pancreatic insulin 1 mRNA expression was significantly up-regulated by either 
Aroclor 1260 (5.8-fold) or PCB 126 (1.4-fold)  exposure, but was signficantly down-
regulated by the Aroclor 1260/PCB 126 mixture (0.25-fold) (Fig. 2.9 A). A similar pattern 
was seen for the beta cell identity gene,  Nkx6-1 (Fig. 2.9 B), and for the F-cell gene product, 
pancreatic polypeptide (Fig. 2.9 C). The nuclear receptors NR4a1 and NR4a3 are involved 
in Nkx6-1 regulated islet beta cell proliferation (107). As with mRNA expression of Nkx6-
1, the mRNA expression levels of  NR4a1 and NR4a3 were increased by either Aroclor 
1260 (2.0-fold and 3.1-fold, respectively) or PCB 126 (1.8-fold and 3.0-fold, resectively), 
while the Aroclor 1260/PCB 126 exposure reduced NR4a1 and NR4a3 mRNA expression 
compared to either exposure alone (Fig. 2.9 D&E). These findings demonstrate that 
exposure to the NDL/DL-PCB mixture was associated with decreased expression of genes 
regulating pancreatic beta cell identity, and this was associated with decreased expression 
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Figure 2.9 Effects of PCB exposures on pancreatic gene expression. Pancreatic mRNA 
levels of insulin1(A), Nkx6-1 (B), pancreatic polypeptide (C), NR4a1 (D) and NR4a3 (E) 
were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, 










Effects of PCB exposures on hepatic gluconeogenic gene expression 
Hepatic gluconeogenesis, contributes significantly to glycaemia, particularly in the 
fasting state. The hepatic mRNA level of Pck1, a regulator of gluconeogenesis, was 
significantly increased by PCB 126 exposure (1.6-fold), but was down-regulated by the 
Aroclor 1260/PCB 126 mixture (Fig. 2.10 A). The hepatic gluconeogenic gene, G6P 
mRNA, was significantly down-regulated by either Aroclor 1260 (1.7-fold) or PCB 126 
(1.3-fold) exposure compared to vehicle control group; while the Aroclor 1260/PCB 126 
mixture up-regulated G6P mRNA expression compared to either exposure alone (Fig. 2.10 
B). Thus, hepatic carbohydrate metabolism was also affected by PCB exposures. Perhaps 
consistent with decreased hepatic gluconeogenesis, the fasting blood glucose was 
decreased by PCB 126 exposure, either alone or along with Aroclor 1260 (Fig. 2.10 C). 
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Figure 2.10 Effects of PCB on gluconeogenic genes expression. Hepatic mRNA levels of 
gluconeogenic genes G6P (A) and Pck1 (B) were measured by performing RT-PCR. (C) 
Fasting blood glucose. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 





The exposure protocol to Aroclor 1260 used in this study is the same, which we have 
used in previous 12-week studies (59, 108). This exposure was designed to mimic the PCB 
bioaccumulation pattern and the highest levels of exposure seen in humans (52). However, 
Aroclor 1260 has lower levels of DL-PCBs than in human bioaccumulation patterns. To 
compensate for lower levels of DL-PCBs, we added a small quantity of PCB 126 that 
represents approximately 0.02 % of a human’s total PCB exposure based on NHANES data 
(42). Because PCB 126 is not the only DL-PCB and human exposures vary, the PCB 126 
dose was increased to 0.1 % (20 µg/kg).    
This PCB 126 dose is much lower (20 μg/kg) than that used in other studies (1.6 mg/kg) 
in the literature (48), but it was sufficient to activate the prototypical AhR target gene, 
Cyp1a2. The induction of Cyp1a2 mRNA was equal in both the PCB 126 alone group and 
in the Aroclor 1260/PCB 126 mixture-exposed groups. This confirms our previous results 
that Aroclor 1260 at this dose does not activate AhR (59), most likely due to the low levels 
of DL-PCBs in the commercial Aroclor 1260 mixture.  
Activation of CAR can either occur from direct by ligand binding or indirect activation 
via inhibition of EGFR (95). The consequences of the different modes of activation of CAR 
are significant as direct CAR activation may have more limited effects in the cell than 
indirect activation. PCB dependent inhibition of EGFR signaling causes extensive changes 
in the mouse phosphoproteins, which includes PI3K. ERK, STAT3, raf (93). In this study, 
all exposures increased CAR target gene Cyp2b10 mRNA expression. The increases were 
far greater with Aroclor 1260 or the Aroclor 1260/PCB 126 mixture exposure > 1000-fold 
while PCB 126 exposure increased Cyp2b10 mRNA expression a more modest 20-fold. 
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This most likely reflects the large difference in dose (mg vs. µg), but confirms our 
observation that PCB 126 is a good inhibitor of EGFR (94). Interestingly, the induction of 
Cyp2b10 mRNA by Aroclor 1260 alone was greater than the induction by the Aroclor 
1260/PCB 126 mixture, indicating that mixtures do not behave in the same way as either 
PCB preparation alone. These results suggest that activation of AhR affected other PCB-
regulated transcription factors. Similar results were obtained with Cyp3a11, where only 
Aroclor 1260 induced this gene and the effects of the mixture appeared no different than 
that seen in the control animals. Thus, it appears that there is interaction between the AhR 
and the nuclear receptors, CAR and PXR.   
The effects of the various PCB exposures on biomarkers of liver disease are more 
complex. Exposure to PCB 126 alone increased liver triglycerides and free fatty acids, 
while the addition of Aroclor 1260 reduced liver triglycerides and fatty acids to close to 
control levels. This is consistent with previous studies in the literature demonstrating that 
activation of AhR in mice spontaneously induced hepatic steatosis (70, 71) and caused 
mice to be much more sensitive to methionine choline-deficient (MCD)-induced NASH 
(109). Likewise, this is consistent with our previous 12-week study in Aroclor 1260 
exposed animals in which steatosis did not get worse. However, Aroclor 1260 exacerbated 
steatohepatitis in 42 % calories from fat mice but had little effect on 10.2 % calories from 
fat control diet. In contrast, direct activators of CAR, such as TCPOBOP, decrease hepatic 
steatosis in HFD-fed type 2 diabetic models and in the ob/ob mice (85, 86). All of these 
data likely reflect the different modes of activation of CAR as PCBs in murine systems are 
indirect activators.    
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Activation of the AhR is known to be associated with dyslipidemia and a wasting 
syndrome. In our current study we observed reductions in serum cholesterol and both HDL 
and nHDLc form, suggesting both increased hepatic import and decreased secretion. 
Likewise, serum triglycerides and VLDL were also reduced. This is consistent with a 
wasting syndrome in which peripheral fat is being mobilized and steatosis results. 
Interestingly, these affects occur in all groups that received PCB 126 and are independent 
of effects caused by Aroclor 1260 exposure. The hypolipidemia induced by PCB 126 
exposure is clearly different from the steatosis caused by hypercaloric diets where these 
parameters rise in concert with the development of steatosis.     
The effects of each exposure on genes involved in lipid metabolism are also more 
complex. For example, the mixture of PCB 126 and Aroclor 1260 slightly decreased the 
level of PPARα, while PCB 126 slightly induced CPT1a and Cyp4a11, and the mixture 
slightly attenuated the effect with CPT1a. In fact, it augments the effect with Cyp4a11. 
Thus, it is highly unlikely this is a PPARα-dependent process but more likely other 
transcription factors are involved in the promotors of these gene are involved.   
Many other genes involved in fat mobilization are affected by PCB exposure. As 
anticipated from previously published studies exposure to either Aroclor 1260 or PCB 126 
induced mRNA expression of Cd36. Interestingly, the mixture of both of these exposures 
actually reduced the expression of this gene that may in part explain why the steatosis was 
less pronounced in the Aroclor 1260/PCB 126 mixture group. A similar pattern is observed 
in the Fabp1 mRNA expression, suggesting a conservation of mechanism while the 
opposite pattern is observed with Fasn. Other genes in fat metabolism and disposition are 
also affected including Scd1, which is negatively regulated by both Aroclor 1260 and PCB 
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126 in a simple additive fashion suggesting independent mechanisms. Finally, the mutated 
Pnpla3 gene results in accumulated lipids and inhibited VLDL secretion. These mutant 
versions are strongly linked to the development of NASH in the human population. This 
gene is induced by Aroclor 1260, but suppressed by PCB 126 and the combination of both 
suppresses the mRNA expression further. In concert these results clearly demonstrate that 
mixtures of DL/NDL-PCBs mixture do not act like their individual components and that 
considerable crosstalk exists between these signaling mechanisms. 
In our study, NDL/DL-PCB mixtures definitely caused structural alterations in 
pancreas, as indicated by pancreatic fibrosis, acinar atrophy and acinar cell steatosis. 
However, there was no definite evidence of diabetes (normal HOMA-B, and decreased 
fasting glucose). Regarding translation to human disease, acinar cell steatosis has not been 
described in humans. However, PCB mixtures seem to cause a pancreatopathy, similar to 
that seen in diabetes, named diabetic exocrine pancreatopathy (110), and also exposures to 
pancreato-toxins such as smoking and alcohol, neither of which is associated with diabetes. 
We propose the term PCB-induced pancreatopathy to describe this condition. Just as in 
other forms of pancreatopathy, the clinical significance of the findings need further study. 
The unchanged HOMA-B in mice may be due to sufficient beta cell reserve at this 
timepoint in mice that were not stressed by obesity. The histological changes were 
paralleled by decreased mRNA expression of insulin 1, pancreatic polypeptide, and islet 
identity factors (e.g., Nkx6-1, NR4a1, and NR4a3). The combination of molecular and 
histological changes suggest that the Aroclor 1260/PCB 126 mixture exerted pancreatic 
endocrine and exocrine toxicity. However, neither Aroclor 1260 nor PCB 126 alone 
demonstrated this pancreatic toxicity. These results are broadly consistent with those of 
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earlier studies in which long-term PCB 126 exposure caused early β-cell failure (111). Lin 
et al. reported that chronic exposure to Aroclor 1254, caused pancreatic atrophy by 
reducing proliferation (112). Aroclor 1254 altered islet β-cell mass and impaired insulin 
receptor signaling, and ultimately disrupted glucose homeostasis (113). Our findings 
extend these observation by demonstrating that PCB exposure can possibly affect the 
genetic programing responsible for islet differentiation and function (e.g. islet identity 
factors). The islet identity factors are transcription factors involved in pancreatic 
differentiation and beta cell homeostasis in utero and in the adult. In rat islets, Nkx6-1 
regulates the expression of glucagon, and controls glucose-stimulated insulin secretion 
(GSIS) (114). The alteration of Nkx6-1 expression was observed in type 2 diabetes patients 
(115). These results suggest alteration of islet identity factors may be involved in endocrine 
disruption by endocrine and metabolism disrupting chemicals (EDCs/MEDs) exposure. In 
the present study, the observed islet identity factors changes were a novel finding in PCB 
exposed mice, and more work is required to determine mechanisms of action. 
Hepatokines have been proposed as being involved in mechanisms involved in the 
development of diabetes, as well as, NAFLD/NASH. These hepatokines include FGF21, 
IGF1 and betatrophin. FGF21 is a member of fibroblast growth factors (FGF) family, and 
plays a critical role in regulation of obesity, insulin resistance and fatty liver disease (116) 
by increasing brown adipose levels and adiponectin secretion. In the current study, mRNA 
levels of Fgf21 were downregulated in both Aroclor 1260 and PCB 126 treated groups, 
while Aroclor 1260/PCB 126 mixture exposure resulted in increased Fgf21 mRNA levels 
compared to individual exposures. As our mice were fasted, the Fgf21 expression in the 
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PCB 126-exposed mice is consistent with the concept that AhR induces FGF21 in the fed-
state, but suppresses FGF21 in the fasted-state (117).  
Another hepatokine that has been implicated both in diabetes and the control of serum 
triglycerides and LDL metabolism is betatrophin (ANGPT8) as reviewed (118). 
Betatrophin expression is low in fasted animals and rises in the fed state and regulates 
triglyceride metabolism (119) by inhibiting lipoprotein lipase (LPL), thereby, decreasing 
LDL sand VLDL uptake by adipocytes. The functions of betatrophin in diabetes are 
controversial but studies suggest it promotes pancreatic β cell proliferation, expanding β 
cell mass, and improves glucose tolerance (105). Regardless, in the current study, 
expression of betatrophin mRNA was significantly upregulated by Aroclor 1260 exposure, 
but not by PCB 126 exposure. Adding PCB 126 to Aroclor 1260 abolished Aroclor 1260-
induced betatrophin expression. PCBs exposure-induced dysregulation of hepatokines 
clearly demonstrates that PCBs and potentially other endocrine and metabolism disrupting 
chemicals (EDCs/MDCs) may affect expression of those hepatokines, such as FGF21 and 
betatrophin. 
In conclusion, even an exposure as low as 20 µg/kg of PCB 126 induced AhR-
dependent genes in mouse liver. Mixtures of DL and NDL PCBs exhibited different effects 
on gene expression, fatty liver disease, and diabetes endpoints, likely due to receptor 
interaction with each other. This suggests that studying single congeners in isolation may 
lead to potentially misleading results when modeling the metabolic disease associated with 
human PCB exposures. PCB 126 produced phenotypically were liver disease, while 
exposure to the mixture of PCB 126 plus Aroclor 1260 induced were pancreatic disease. 
Several novel targets for endocrine/metabolic disruption were identified including 
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PNPLA3, islet identity factors, and hepatokines. The latter implied that the liver is both a 
target and effect organ for endocrine disruption. More research is required to better 





THE INTERACTION OF DIET AND POLYCHLORINATED BIPHENYLS IN 
REGULATION OF NON-ALCOHOLIC STEATOHEPATITIS 
1. Introduction 
High calorie intake or a Western diet induces NAFLD, and environmental pollutants 
serve as “second hit” to exacerbate high fat diet-induced liver injury in murine models (37). 
For example, a 20 mg/kg exposure to Aroclor 1260 has no effect on liver injury and hepatic 
pathological changes in control diet fed mice, but a high fat diet fed mice developed 
neutrophil infiltration, liver injury. Thus, Aroclor 1260 drives hepatic steatosis progression 
to steatohepatitis in high fat diet fed mice. Moreover, a high fat diet suppresses CAR 
activation, and decreases its target genes’ expression induced by Aroclor 1260 exposure.  
Our acute exposure results demonstrated either Aroclor 1260 or PCB 126 exposure affected 
hepatic lipid metabolism, while only PCB 126 exposure induced mild hepatic steatosis. 
Co-administration of Aroclor 1260 and PCB 126 reduced the mild steatosis. With the 
increasing incidence of obesity and type 2 diabetes patients worldwide, a higher incidence 
of NAFLD is being observed, and the role of PCB exposures in these require investigation 
(42). The purpose of this chronic exposure study was to perform an analysis of liver and 
serologic endpoints using exposures that better mimic a high level human exposure to 
examine if the murine AhR is preferentially activated and whether or not mixtures of DL- 
and NDL-PCBs will behave like each component alone in high fat diet fed mice will be 
investigated. The animal groups and PCB treatments were the same as the acute exposure 
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2. Materials and Methods 
Reagents 
Please refer to Chapter 3 section for details. Humulin R (100 U/mL) was obtained from 
Eli Lilly, (Indianapolis, IN). Primary antibody (F4/80, ab6640) and second antibody were 
supplied by Abcam, (Cambridge, MA). CAE, Naphthol AS-D Chloroacetate (Specific 
Esterase) Kit were obtained from Sigma-Aldrich, (St. Louis, MO). 
Animal exposures 
The animal protocol used was approved by the University of Louisville Institutional 
Animal Care and Use Committee. Male C57BL/6j mice (10 weeks old) were obtained from 
The Jackson Laboratory, (Bar Harbor, ME), and divided into 4 groups (n=10).  All the mice 
were fed a high fat diet (15.2 %, 42.7 %, and 42.0 % of total calories come from protein, 
carbohydrate, and fat, TekLab TD88137). Mice were treated by one-time gavage with 
either Aroclor 1260 (20 mg/kg), PCB 126 (20 µg/kg), Aroclor 1260 (20 mg/kg) with 0.1 % 
PCB 126 (20 µg/kg) or vehicle control (corn oil) for 12 weeks. Glucose tolerance test (GTT) 
and insulin tolerance test (ITT) were performed at 8 and 10 weeks, respectively, prior to 
euthanasia. Mice were housed in a temperature- and light controlled-room (12 h light; 12 
h dark) with food and water ad libitum. The animals were euthanized at the end of week 
12 using ketamine/xylazine (100/20 mg/kg body weight, i.p.) and the blood, liver, and fat 
tissues were collected. Dual energy X-ray absorptiometry (DEXA) scanning (Lunar 







Please refer to Chapter 3 section for detail. Additional chloroacetate esterase activity 
and macrophage accumulation were measured using CAE and immunohistochemistry 
(IHC) staining according to manufacturer’s protocols, respectively. 
Real-time PCR 
Please refer to Chapter 3 section for detail. Additional probes and their sequence were 
as follows: Tgf-β1 (Mm01178820_m1), Acta2 (Mm00725412_s1), Collagen (Col) 1a1 
(Mm00801666_g1), Collagen (Col) 1a2 (Mm00483888_m1), and TIMP1 
(Mm00441818_m1). 
Measurement of hepatic lipid 
Please refer to Chapter 3 section for detail. 
Measurement of plasma lipid and cytokine 
Please refer to Chapter 3 section for detail. 
Glucose and insulin tolerance test 
For the glucose tolerance test, mice were fasted for 16 hours prior to test. The basal 
fasting blood glucose levels were measured using a glucometer (ACCU-CHECK Aviva, 
Roche, Basel, Switzerland) with one drop of tail vein blood. Then sterile glucose was 
administrated via intraperitoneal (i.p.) injection at dose of 1 g/kg body weight within 15 
minutes, and blood glucose levels were measured at 15, 30, 60, and 120 minutes post 
injection.  
For the insulin tolerance test, mice were fasted for 6 hours at the day of test. Following 
a determination of the basal glucose level, sterile insulin was administrated, via 
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intraperitoneal (i.p.) injection, at dose of 0.5 U/kg body weight within 15 minutes, and 
blood glucose levels were measured at 15, 30, 60, and 120 minutes post injection.  
Statistical analysis 























Effects of PCB exposures on body weight and composition 
AhR activation induced by a high dose of pollutant agonist exposure, such as TCDD, 
leads to a wasting syndrome, characterized by a loss of body weight associated with a 
decrease in adipose tissue mass (120). To evaluate whether PCB exposures induced a 
wasting syndrome, body weight was monitored weekly. The body weight gradually 
increased in all groups regardless of PCB exposures due to high fat diet used in this 
experiment (Fig. 3.1 A). However, there were no changes in body weight (Fig. 3.1 B) or 
fat composition (Fig. 3.1 C) in PCB exposure groups compared to control group. The 
liver/body weight ratio was not changed after PCB exposures (Fig. 3.1 D); and the 
epididymal fat/body weight ratio was increased only after Aroclor 1260 exposure, but not 
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Figure 3.1 Effects of PCB exposures on body weight and composition after 12 weeks 
exposure. (A) Body weight changing, (B) body weight, (C) body fat composition, (D) the 
ratio of liver weight to body weight, (E) the ratio of epididymal fat weight to body weight. 
Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 effects. 
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Effects of PCB exposures on AhR, CAR and their target genes 
As shown in chapter 2, different types of PCB exposures are associated with AhR and 
CAR activation in mice fed control synthetic diet. AhR mRNA expression was decreased 
by PCB 126 (0.5-fold) exposure, but not by the other PCB exposed groups (Fig. 3.2 A). 
PCB 126 alone or Aroclor 1260/PCB 126 mixture activated AhR, as indicated by 4.0-fold 
or 2.6-fold induction of the AhR target gene Cyp1a2 mRNA expression, respectively. 
Adding PCB 126 to Aroclor 1260 resulted in a reduction of Cyp1a2 mRNA expression 
compared to PCB 126 alone (Fig. 3.2 B). CAR mRNA expression was significantly 
increased by PCB 126 alone (1.6-fold) or in the Aroclor 1260/PCB 126 mixture (2.3-fold), 
but was not changed by Aroclor 1260 (Fig. 3.2 C). The CAR-dependent gene Cyp2b10 
mRNA was increased by Aroclor 1260 (6.5-fold) or Aroclor 1260/PCB 126 mixture (2.3-
fold) exposure (Fig. 3.2 D).  Addition of PCB 126 reduced the Aroclor 1260-dependent 
induction of Cyp2b10, indicating an interaction between AhR and CAR signaling (Fig. 3.2 
D). However, the extent of AhR or CAR transcriptional activities were affected by diet 
effects, since high fat diet suppressed PCB exposures-induction of the AhR target Cyp1a2 
slightly (≈50%). AS anticipated (37), decreased induction CAR-target Cyp2b10 
dramatically (≈1000-fold) activity when compared with control synthetic diet fed mice 
treated with same dose of PCBs. Moreover, the conclusions made in chapter 2 that the 
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Figure 3.2 Effects of PCB exposures on AhR, CAR and their target genes. Hepatic mRNA 
levels of AhR (A) and target gene Cyp1a2 (B), CAR (C) and target gene Cyp2b10 (D) were 
measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= 










Effects of PCB exposures on hepatic steatosis 
H&E staining data demonstrated mice fed on high fat diet developed variable, 
centrilobular, macrovesicular lipidosis (hepatic steatosis), and PCB exposures did not 
exacerbate high fat diet-induced hepatic steatosis (Fig. 3.3 A). Neither hepatic triglyceride 
(Fig. 3.3 B) nor cholesterol (Fig. 3.3 C) levels were significantly affected by either PCB 
exposures, however, hepatic free fat acid levels were significantly increased by PCB 126 
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Figure 3.3 Effects of PCB exposures on hepatic steatosis. (A) H&E staining of liver (10 ×). 
High fat diet induced variable, centrilobular, macrovesicular lipidosis, and PCBs exposure 
did not exacerbate high fat diet-induced steatosis in liver. (B) hepatic triglycerides levels, 
(C) hepatic cholesterol levels, (D) hepatic free fatty acid levels. n=10. Data are presented 




Effects of PCB exposures on liver injury 
Previous studies showed that Aroclor 1260 exposure serves as “second hit” to drive 
hepatic steatosis to advanced steatohepatitis, therefore, plasma alanine (ALT) or aspartate 
(AST) aminotransferase levels were measured. Plasma ALT levels were elevated by 
Aroclor 1260 alone exposure (1.9-fold), but not by PCB 126 exposure. The mixture of PCB 
126 and Aroclor 1260 attenuated Aroclor 1260-elevated plasma ALT levels (Fig. 3.4 A), 
suggesting that PCB 126 was protective against liver injury in this model. Likewise, PCB 
126 exposure also showed a suppression of plasma AST levels when either given alone or 
mixed with Aroclor 1260 (Fig. 3.4 B). Hepatic mRNA expression of Tnfα was increased 
by either Aroclor 1260 exposure (1.8-fold) or Aroclor 1260/PCB 126 mixture exposure 
(1.9-fold) compared to vehicle group (Fig. 3.4 C). Likewise, hepatic mRNA expression of 
Ccl8 was significantly induced by Aroclor 1260 exposure (3.3-fold), suppressed by PCB 
126 alone exposure (0.38-fold), and mixture of PCB 126 of Aroclor 1260 abolished Aroclor 
1260 exposure-induced Ccl8 mRNA expression (Fig. 3.4 D). The similar patterns of 
mRNA levels of Ccl3 (Fig. 3.4 E) and Cxcl1 (Fig. 3.4 F) were also observed. In concert, 
these results demonstrated that addition of PCB 126 attenuates liver injury as evidenced by 









      A                                          B                                           C 
 
       D                                          E                                           F 
     
 
Figure 3.4 Effects of PCB exposures on liver injury. (A) Plasma ALT and (B) AST levels. 
Hepatic mRNA levels of Tnfα (C), Ccl8 (D), Ccl3 (E), and Cxcl1 (F) were measured by 
performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 










Effects of PCB exposures on hepatic inflammatory response 
Neutrophil and macrophage infiltration lead to liver injury, thus, CAE and 
immunohistochemistry (F4/80, a macrophage marker) staining were performed to evaluate 
neutrophil infiltration and macrophage accumulation in liver, respectively. CAE staining 
showed high fat diet induced neutrophil infiltration, and Aroclor 1260 exposure 
exacerbated this effect. PCB 126 alone or in a Aroclor 1260/PCB 126 mixture did not 
display the elevated neutrophil infiltration (Fig. 3.5 A&B). Likewise, more F4/80 positive 
brown cells were found by Aroclor 1260 exposure compared to vehicle group, while PCB 
126 or Aroclor 1260/PCB 126 mixture were not elevated (Fig. 3.5 C). This result was also 
confirmed by measurement of gene expression of another macrophage maker, CD68. 
Aroclor 1260 exposure increased CD68 mRNA expression by 1.4-fold compared to vehicle 
group, and mixture of PCB 126 of Aroclor 1260 reversed Aroclor 1260-induced CD68 
mRNA expression (Fig. 3.5 D). These results suggested Aroclor 1260 exposure, but not 
PCB 126 exposure, induced inflammatory cell infiltration and led to liver injury, and PCB 
126 displayed anti-inflammation effects which likely accounts for the reduced plasma liver 










                       A                                                             
                                              Control                                    Aroclor 1260 
   
                                             PCB 126                            Aroclor 1260/PCB 126 
   
                       C 
                                             Control                                      Aroclor 1260 
   
                                        PCB 126                            Aroclor 1260/PCB 126 






                   B                                                           D 
               
 
Figure 3.5 Effects of PCB exposures on hepatic inflammatory response. (A) CAE staining 
(40 ×). Red positive cells indicate neutrophil infiltration, (B) CAE positive number per 
field, (C) F4/80 immunohistochemistry staining (20 ×). Brown positive cells indicate 
macrophage accumulation, (D) hepatic CD68 mRNA levels. Data are presented as mean ± 














Effects of PCB exposures on plasma lipids and adipokines  
PCB 126 exposure led to hypolipidemia in control synthetic diet fed mice in the2-week 
study. In high fat diet fed mice, PCB 126 alone or Aroclor 1260/PCB 126 exposure also 
decreased plasma triglycerides, but Aroclor 1260 exposure did not affect this variable (Fig. 
3.6 A).  Either Aroclor 1260 or PCB 126 exposure did not alter plasma total cholesterol, 
while co-administration of Aroclor 1260 and PCB 126 decreased total cholesterol (Fig. 3.6 
B). The plasma levels of PAI-1, which is implicated in the pathogenesis of fibrosis (121), 
were significantly decreased by PCB 126 exposure (Fig. 3.6 C). Moreover, adipokines, 
including adiponectin (Fig. 3.6 C), leptin (Fig. 3.6 D) and resistin (Fig. 3.6 E) were not 
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Figure 3.6 Effects of PCB exposures on plasma lipids and adipokines. Plasma levels of 
triglyceride (A), total cholesterol (B), PAI-1 (C), adiponectin (D), leptin (E), and resistin 
(F). Data are presented as mean ± SEM. n=10. p<0.05, b= PCB 126 effects, c= interaction 











Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression 
Unlike the effects of PCB exposures on fatty acid β-oxidation genes expression in the 
2-week study, hepatic mRNA levels of Pparα and target gene Cpt1α were decreased by 
either Aroclor 1260, PCB 126 or Aroclor 1260/PCB 126 mixture exposure (Fig. 3.7 A&B). 
Pparα mRNA expression was decreased by 9.1 %, 11.6 % and 20.1 % by Aroclor 1260, 
PCB 126, and Aroclor 1260/PCB 126, respectively (Fig. 3.7 A). Cpt1α mRNA expression 
was decreased by 5.1 %, 2.8 % and 13.6 % by Aroclor 1260, PCB 126, and Aroclor 
1260/PCB 126, respectively (Fig. 3.7 B). However, the mRNA expression of Cyp4a10 had 
the same pattern as my 2-wwek study. PCB 126 increased Cyp4a10 mRNA expression 1.2-
fold while the Aroclor 1260/PCB 126 mixture increased 1.5-fold (Fig. 3.7 C). These data 
suggested that the interaction of diet and PCB exposures affect reduction of mitochondrial 
fatty acid β-oxidation but increased peroxisomal fatty acid β-oxidation. 
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Figure 3.7 Effects of PCB exposures on hepatic fatty acid β-oxidation genes expression. 
Hepatic mRNA levels of Pparα (A), Cpt1a (B), and Cyp4a10 (C)were measured by 
performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, a= Aroclor 1260 
effects, b= PCB 126 effects, c= interaction between Aroclor 1260 and PCB 126. 
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Effects of PCB exposures on other genes of hepatic lipid metabolism 
mRNA levels of Cd36 were significantly increased by either PCB 126 (1.3-fold) or 
Aroclor 1260 (1.3-fold) exposures, and the additive induction by PCB 126 and Aroclor 
1260 on Cd36 mRNA levels were found with the Aroclor 1260/PCB 126 mixture exposure 
(1.5-fold) (Fig. 3.8 A). Either PCB 126 exposure slightly suppressed Fabp1 mRNA 
expression, but Aroclor 1260/PCB 126 mixture exposure induced Fabp1 mRNA 
expression compared to either exposure alone (Fig. 3.8 B). Both Srebp1 (13.9 %) and Fasn 
(25.2 %) mRNA levels were decreased by PCB 126 exposure, but not by the Aroclor 1260 
exposure. However, co-administration of PCB 126 and Aroclor 1260 resulted in slightly 
increased Srebp1 mRNA compared to PCB 126 alone exposure, and suppressed Fasn 
mRNA expression compared to vehicle group (Fig. 3.8 C&D). Likewise, Scd1 mRNA 
expression was decreased by either Aroclor 1260 (9.3 %) or PCB 126 (14.5 %) exposure, 
and in an additive manner by the Aroclor 1260/PCB 126 mixture (23.9 %) exposure (Fig. 
3.8 E). Pnpla3 mRNA expression was significantly upregulated by Aroclor 1260 (1.6-fold) 
exposure, but was suppressed by either PCB 126 (42.2 %) or Aroclor 1260/PCB 126 
(37.5 %) exposure (Fig. 3.8 F). These data suggested that PCB exposures increased hepatic 
lipid levels due to increased lipid uptake, not by increasing de novo lipogenesis. Moreover, 
high fat diet suppressed PCB exposures-induced lipid metabolic gene expression when 
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Figure 3.8 Effects of PCB exposures on other genes of hepatic lipid metabolism. Hepatic 
mRNA levels of Cd36 (A), Fabp1 (B), Srebp1 (C), Fasn (D), Scd1 (E), and Pnpla3 (F) 
were measured by performing RT-PCR. Data are presented as mean ± SEM. n=10. p<0.05, 





Effects of PCB exposures on glucose metabolism 
PCB exposures are associated with diabetes in human populations. To determine 
whether PCB exposures affect glucose metabolism, glucose and insulin tolerance tests 
were performed. PCB exposures did not impair glucose tolerance and insulin sensitivity, 
as indicated by similar area under curves (AUCs) for all PCB exposures compared to the 
control group (Fig. 3.9 A&B). However, PCB 126 exposure suppressed gluconeogenic 
gene (Pck1) mRNA expression, and decreased fasting blood glucose levels (Fig. 3.9 C&D). 
Our current data are consistent with the published results by Diani-Moore S et al that 
activation of AhR suppressed gluconeogenic genes (Pck1) mRNA expression by TCDD 
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Figure 3.9 Effects of PCB exposures on glucose metabolism. (A) Glucose tolerance test 
and area under curve (AUC); (B) insulin tolerance test and area under curve (AUC); (C) 
fasting blood glucose levels; hepatic mRNA levels of Pck1 (D) and G6P (E) were measured 




Effects of PCB exposures on hepatic fibrosis 
Activated HSCs are the major source of extracellular matrix (ECM), including 
collagen, deposition in liver fibrosis. The balance of ECM is regulated by MMPs and 
TIMPs. To evaluate whether PCB exposures induced hepatic fibrosis, mRNA expression 
levels of fibrosis genes (e.g., TGF-β1, Acta2, Col 1a1, Col 1a2, MMPs, TIMP1, and PAI1) 
were measured. Although TGF-β1 mRNA expression was not affect by all PCB exposures 
(Fig. 3.10 A), PCB 126 alone exposure suppressed hepatic stellate cells (HSCs) activation, 
as indicated by decreased Acta2 (48.3 %) mRNA expression (Fig. 3.10 B). Moreover, 
mRNA expression of Col 1a1 (40.5 %) (Fig. 3.10 C), Col 1a2 (55.6 %) (Fig. 3.10 D), 
TIMP1 (64.6 %) (Fig. 3.10 E), and PAI1 (72.5 %) (Figure 3.10 F) were significantly 
decreased by PCB 126 exposure, but not by Aroclor 1260 exposure. The mRNA levels of 
ECM degradation genes, including MMP2 (Fig. 3.10 G), MMP9 (Fig. 3.10 H), and MMP14 
(Fig. 3.10 I), were not significantly changed by all PCB exposures. Co-administration of 
Aroclor 1260 and PCB 126 did not attenuate PCB 126 exposure-induced changes in mRNA 
levels of these genes. Surprisingly, although PCB 126 exposure alone suppressed fibrotic 
genes mRNA levels, histological data showed that the collagen deposition was similar with 
all PCB exposures, as shown by picrosirius red staining (Fig. 3.10 J). However, mRNA 
changes may proceed pathological changes. These data suggested that fibrotic genes were 
altered by PCB exposures, but failed to cause phenotypical changes in fibrosis. Longer 
time and/or higher dose exposure, or the carbon tetrachloride-induced fibrosis model, 
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Figure 3. 10 Effects of PCB exposures on hepatic fibrosis. Hepatic mRNA levels of TGF-
β1 (A), Acta2 (B), Col 1a1 (C), Col 1a2 (D), TIMP1 (E), PAI1 (F), MMP2 (G), MMP9 (H), 
and MMP14 (I) were measured by performing RT-PCR. (J) picrosirius red staining of liver 











The acute PCB exposure study (chapter 3), mice fed control synthetic diet developed 
hepatic steatosis and activation of AhR with PCB 126 exposure. Aroclor 1260/PCB 126 
exposure also activated AhR, but failed to induce hepatic steatosis. In the current study, 
the interactions of diet and PCB exposures in regulation of NAFLD/NASH were 
investigated. I hypothesize that activation of AhR is involved in the development and 
progression of NAFLD/NASH after PCB exposures in high fat diet fed mice. The results 
demonstrated that high fat diet induced hepatic steatosis regardless of PCB exposure, 
Aroclor 1260 (20 mg/kg) exposure promoted progression of hepatic steatosis to 
steatohepatitis, while PCB 126 (20 µg/kg) exposure appeared to reverse HFD-induced 
hepatic fibrosis. Co-administration of PCB 126 of Aroclor 1260 abrogated Aroclor 1260 
exposure-induced steatohepatitis.  
Aroclor 1260 is a mixture of NDL-PCB congeners. It contains low amounts of DL 
PCB congeners. Aroclor 1260 exposure at this level failed to induce the AhR target gene, 
Cyp1a2 mRNA level in mice on either chow diet in 2-week study or with a high fat diet in 
the current study. These data are consistent with previous results demonstrating that 
Aroclor 1260 (20 mg/kg) did not activate AhR, but a high exposure of Aroclor 1260 (200 
mg/kg) did (59).  In the acute study (chapter 3), either PCB 126 or Aroclor 1260/PCB 126 
mixture activated AhR, and co-administration of Aroclor 1260 with PCB 126 did not affect 
PCB 126-induced AhR activity. In the current study, AhR activity was increased by PCB 
126 alone exposure, but the magnitude of AhR-dependent induction was decreased 
compared to the results seen in the acute study. Co-administration of Aroclor 1260 in the 
Aroclor 1260/PCB 126 mixture attenuated PCB 126 exposure-induced AhR activity. These 
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data suggested that high fat diet affects the magnitude of PCB 126 exposure-induced AhR 
activity. Moreover, high fat diet also impacted Aroclor 1260 exposure-induced CAR and 
PXR target gene expression. For example, CAR target gene Cyp2b10 mRNA was induced 
at least 1000-fold by either Aroclor 1260 or Aroclor 1260/PCB 126 mixture in mice fed on 
control chow diet as shown in chapter 3. However, less than 10-fold induction of Cyp2b10 
mRNA by either Aroclor 1260 or Aroclor 1260/PCB 126 mixture was found. The 
magnitude of induction of Cyp2b10 mRNA by PCB 126 exposure, as shown in chapter 3, 
was also abolished by high fat diet.  
High dose of TCDD (120) or PCB 126 (123) exposure causes a wasting syndrome. 
However, in the current study, neither PCB 126 nor Aroclor 1260/PCB 126 mixture 
exposure resulted in a wasting syndrome, as indicated by no significant body weight or 
epididymal fat tissue weight changes compared to the control group, although activation 
of AhR can be observed at lower doses of PCB 126 exposure (20 µg/kg VS. 4.9 mg/kg). 
Moreover, epididymal fat tissue weight was significantly increased by Aroclor 1260 
exposure, possibly due to NDL-PCB 153 serving as an obesogen (124). Similar results 
were found in control synthetic diet fed mice in chapter 3. In low fat diet fed rats, PCB 126 
exposure induced hepatic steatosis (73, 125), associated with altered hepatic micronutrients 
(96, 126). Our previous acute study results confirm these data that only PCB 126 exposure 
led to hepatic steatosis in control synthetic diet fed mice. However, in the current study, 
histological results showed that high fat diet induced hepatic steatosis alone, and PCB 
exposures did not exacerbate high fat diet-induced hepatic steatosis. These results were 
also confirmed by hepatic lipid levels measurement. As shown above, no PCBs exposure 
had effects on hepatic triglycerides or total cholesterol levels. However, PCB 126 exposure 
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increased hepatic free fatty acid levels compared to control group. These data suggest 
interactions between diet and PCB 126 exposure may affect AhR activation-induced 
hepatic steatosis. This may be due to the lipophilic property of PCBs, which may restrict 
PCBs distribution in high fat diet conditions and metabolic stress.  
As mentioned in the discussion section of chapter 3, activation of CAR can be direct 
by ligand binding or indirect via inhibition of EGFR signaling (95). Direct activation of 
CAR by agonist, TCPOBOP, ameliorates metabolic syndromes, such as obesity, type 2 
diabetes and NAFLD/NASH in mice under pathological conditions (85-87). However, 
mice administered TCPOBOP displayed hepatic lipogenesis and positive regulation of 
Pnpla3 gene expression. These results suggest the consequences of activation of CAR are 
varied under different conditions by direct ligand activation. Although Aroclor 1260 
exposure induced CAR activation under either physiological condition (low fat diet) or 
pathological condition (high fat diet), Aroclor 1260 exposure had no effects on hepatic 
steatosis or glucose or insulin tolerance. However, Aroclor 1260 alone exposure promoted 
hepatic steatosis progression to steatohepatitis in high fat diet fed mice, which conflicts 
with the fact that direct activation of CAR attenuates NAFLD/NASH. These data suggest 
CAR is indirectly activated by Aroclor 1260 exposure. These data have been confirmed by 
our previous study demonstrating that Aroclor 1260 inhibits hepatic EGFR signaling (93). 
Other data to support this conclusion are that hepatic gluconeogenesis regulation occurs by 
direct CAR activation. CAR activation by agonists suppresses gluconeogenic genes (Pck1 
and G6p) mRNA levels, and suppresses hepatic gluconeogenesis via degradation of 
PGC1alpha protein (91), or inhibition of HNF4a and FOXO1 transcriptional activity (127). 
In my study, Aroclor 1260 exposure did not affect hepatic gluconeogenic genes expression 
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and fasting blood glucose levels in either chow diet or high fat diet fed mice. In addition, 
PCB 126 exposure suppressed gluconeogenic genes expression, and decreased fasting 
blood glucose levels, consistent with previous published data (73, 79, 122).  
In chapter 2, not all PCB exposures caused liver injury, as documented by similar 
plasma ALT and ALT levels compared to the mice on control synthetic diet fed mice, even 
though PCB 126 alone exposure induced mild hepatic steatosis. In the current study, 
Aroclor 1260 exposure induced neutrophils infiltration and macrophages accumulation in 
liver, and increased plasma ALT levels, which has been confirmed by our previous study 
(59). Interestingly, it appears that PCB 126 exposure protected against high fat diet-induced 
liver injury, as PCB 126 alone exposure decreased plasma AST levels, and attenuated 
Aroclor 1260 exposure-elevated plasma ALT levels by co-exposure of Aroclor 1260 and 
PCB 126. This may be due to anti-inflammatory due to AhR activation (128). This 
phenomenon was also found in our previous study that high dose of Aroclor 1260 (200 
mg/kg) activates AhR and fails to cause liver injury (59). These results suggested that AhR 
activation regulates lipid metabolism and immune response through different signaling 
pathways. 
Liver injury activates hepatic stellate cells (HSCs), and results in hepatic fibrosis by 
environmental pollutant exposure. TCDD exposure activates AhR, induces HSCs 
activation, and facilitates liver fibrosis (129, 130). However, TCDD exposure fails to 
exacerbate experimental liver fibrosis, although it increases necroinflammation and HSCs 
activation (131). This may be due to enhanced ECM turnover (132). In addition, high dose 
of PCB 126 exposure exacerbates MCD-induced liver fibrosis (123). In the current study, 
all PCB exposures did not increase collagen deposition or cause liver fibrosis, even though 
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Aroclor 1260 exposure increased liver injury. Surprisingly, PCB 126 exposure suppressed 
fibrotic gene mRNA levels, such as col 1a1, col 1a2, and TIMP1. It also decreased plasma 
PAI1 levels. The reasons for this are unknown, and need further investigation.  
The effects of PCBs exposure on genes involved in lipid metabolism are not like the 
data in acute study. For example, the fatty acid β-oxidation genes mRNA levels are 
increased by either Aroclor 1260 or PCB 126 exposure, but inhibited by Aroclor 1260/PCB 
126 exposure compared to either exposure alone. In the current study, all PCBs exposure 
suppressed fatty acid β-oxidation genes mRNA expression. The gene expression of fatty 
acid transporters mRNA was upregulated by either Aroclor 1260 or PCB 126 exposure in 
both diet, but the Aroclor 1260/PCB 126 mixture exposure displayed opposite results. The 
similar pattern also was found in Pnpla3 and fatty acid synthesis (Fasn) gene. These data 
suggest that unlike Aroclor 1260 or PCB 126 exposure, Aroclor 1260/PCB 126 mixture 
exposure exhibits different effects on genes involved in lipid metabolism with diet 
interaction. The DL/NDL-PCBs mixture should be used to evaluate metabolic endpoints 
in animal model, to allow for better prediction of the endocrine and metabolism disruption 
effects in humans.  
In summary, high fat diet affects AhR, and CAR expression, as well as, their 
transcriptional activity. Aroclor 1260 exposure may indirectly activates CAR, and induces 
liver inflammation and injury; while PCB 126 exposure activates AhR and reduces hepatic 
inflammation, and attenuates Aroclor 1260 exposure-induced liver injury, and fibrosis. 
Moreover, both DL- and NDL-PCBs affect genes of lipid metabolism, which are associated 
with fatty liver disease. Mixtures of DL- and NDL-PCBs exhibit different effects on fatty 




COMPARISON OF CONCENTRATION-DEPENDENCE OFHUMAN AND MOUSE 
ARYL HYDROCARBON RECEPTOR ACTIVATION IN RESPONSE TO 
POLYCHLORINATED BIPHENYL EXPOSURES 
1. Introduction 
PCB congeners can be classified into dioxin-like (DL) and non-dioxin-like (NDL) 
classes. DL-PCBs have non-ortho or mono-ortho substitution and are ligands for the AhR 
since their planar structure allows them to fit well in the binding pocket of that receptor. 
The AhR plays an important role in allowing the liver to be a target for PAH metabolic 
action. Furthermore, other studies have shown that PCBs exposure is associated with liver 
disease (42), diabetes (57), and vascular disease (133), association with AhR activation. 
The AhR is a transcription factor that belongs to the Per-Arnt-Sim family (67). 
Unliganded AhR resides in the cytoplasm of cells and upon ligand binding, translocates to 
the nucleus, forming a heterodimer with AHR nuclear translocator protein (ARNT). The 
AhR-ARNT heterodimer binds to the dioxin response element (DRE) on the 5’-flanking 
regions of most dioxin-responsive genes, and regulates expression of target genes, 
prototypically the Cyp1 family.  
To estimate human risk due to AhR activation by these chemical exposure, the World 
Health Organization (WHO) has established toxic equivalency factors (TEFs) for AhR 
ligands (134). TCDD is considered the prototypical ligand for AhR and therefore, is 
assigned a TEF of 1. The TEFs of other chemicals are calculated based on relative effect 
84 
 
potency (REP) values relative to that of TCDD. PCB 126, a non-ortho substituted PCB, 
which has highest AhR binding affinity of DL-PCBs, has the TEF 0.1 and is the major 
contributor to the total TEQ from PCBs. The TEFs of 29 AhR ligands have been calculated 
and have much lower TEFs than PCB 126. For example, all the TEFs of all mono-ortho 
substituted PCBs are 0.00003 (135).   
However, TEFs are calculated for each AhR ligand in a species-specific manner, so if 
differences exist between the affinity for TCDD or the PCBs relative to TCDD, then there 
will be differences in the exposure levels required to activate the AhR. Previous Studies 
have compared the potency of DL-PCB congeners and/or TCDD in inducing CYP mRNA 
levels in the human and rodent immortalized cell lines and primary hepatocytes (136, 137). 
These data support the conclusion that the sensitivity of human AhR is lower than that of 
the rat in response to TCDD or some DL-PCB congeners exposure. The differences in 
primary amino acid sequence of AhR in ligand-binding pocket (138) and the different 
ability to recruit coactivators by AhR (139) were thought to be responsible for the different 
AhR sensitivity across species. Relatively, less is known about the murine AhR which was 
the species used in our animal studies (59, 140). 
My hypothesis is that the murine AhR activation will respond to DL/NDL-PCBs 
mixture and DL-PCBs with lower concentration-dependence than the human AhR. To 
evaluate the difference of TEFs across human and mouse AhR in response to DL-PCBs 
exposure, human (HepG2) and mouse (Hepa1c1c7) hepatoma-derived cell line were used 
for AhR-dependent luciferase activity, as well as, primary human and mouse hepatocytes 
were used for native Cyp1a1 gene expression. Our results demonstrated that the maximal 
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response for human AhR in increasing gene expression was higher than that in mouse, but 
























2. Materials and Methods 
Reagents 
TCDD, Aroclor 1260, Aroclor 1254 (lot # 124-191) and DL-PCB congeners (PCBs 
77, 81, 114, 126, 169) were purchased from AccuStandard (New Haven, CN). 
Lipofectamine, Opti-MEM and Wamouth’s medium, fetal bovine serum (FBS), Hank's 
Balanced Salt Solution (HBSS, 10X), probes for human CYP1a1 (Hs01054797_g1) and 
GAPDH (Hs02786624_g1), mouse Cyp1a1 (Mm00487218_m1) and GAPDH 
(Mm99999915_g1) for Taqman Gene Expression Assays were ordered from Thermo 
Fisher Scientific (Waltham, MA). Dulbecco's Modified Eagle's Medium (DMEM) was 
purchased from VWR (Radnor, PA), whereas antibiotics, 0.25 % trypsin with EDTA, Type 
1 collagen , and ITSTM + Premix Universal Culture Supplement were obtained from 
Corning Inc. (Corning, NY). Cell culture Lysis 5x buffer and Luciferase Assay System 
were obtained from Promega (Madison, WI). Chlorophenol red-β-D-galactopyranoside 
and Collagenase D were from Sigma-Aldrich, (St. Louis, MO). RNA STAT-60 was from 
amsbio (Austin, TX), and QuantiTect Reverse Transcription Kit was obtained from 
QIAGEN (Qiagen, Valencia, CA). iTag Universal Probes Supermix was purchased form 
Bio-Rad (Hercules, CA). 1,2-benz[a]anthracene (BA), dimethyl sulfoxide (DMSO), 
ethanol, 2-propanol, chloroform and all other reagents were obtained from Sigma Aldrich. 
Cell culture 
The human male HepG2 and mouse Hepa1c1c7 cells were purchased from the 
American Type Culture Collection (Manassas, MD). Cells were cultured in DMEM 
complete medium supplemented with 10 % FBS and 1 % antibiotics, and incubated in 5 % 
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CO2 and 95 % humidity at 37 ◦C. HepG2 cells and Hepa1c1c7 cells were sub-cultured 
every 3-4 days.  
Cell transfection 
The HepG2 and Hepa1c1c7 cells were plated into 24-well plates, and transfected at 
40 %-50 % confluence. In brief, DMEM medium was replaced by Opti-MEM medium 30 
min prior to transfection. Cells were transfected with 150 ng of a pGl3-promoter-based 
reporter plasmid pXRE-SV40-Luc that has been described previously (52)  and  150 ng of 
pCMV-β (Stratagene, CA) using lipofectamine (Thermo-Fisher) according to the 
manufacturer’s instructions. Following an overnight recovery period, the chemicals of 
interest were then added and the cells were grown for 24 hours prior to harvest. DMSO 
was used as a solvent control, and the final concentration was less than 0.2 %. Cells were 
harvested using 1x cell culture lysis buffer. Chlorophenol red β-D-galactopyranoside was 
used to determine β-galactosidase activity to normalize transfection efficiency. Following 
incubation, β-galactosidase enzyme activity was determined spectrophotometrically at 595 
nm using the Bio-Tek Synergy HT multi-mode micro plate reader (Bio-Tek USA, 
Winooski, VT). Luciferase reporter assays were performed with a Promega Luciferase 
Assay System on an Orion L micro plate luminometer (Berthold Detection Systems, 
Pforzheim, Germany).  
Primary mouse hepatocytes isolation 
Livers from 10-week-old male C57BL/6 mice were used to prepare hepatocytes by 
digestion with collagenase D on basis of published protocol (141). Hepatocytes were 
resuspended in cold Waymouth’s medium, and cultured for 12 hours in type 1 collagen 
pre-coated 12-well plates.  
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Cell treatment and RT-PCR 
Primary human hepatocytes were obtained from BioreclamationIVT (Baltimore, MD). 
Primary human hepatocytes were plated according to the supplier’s instructions in 12-well 
plates and cultured overnight. Chemicals of interest at indicated concentration were added 
to primary human and mouse hepatocytes for 24 hours. Cells were lysed and mRNA was 
isolated using STAT-60. RNA purity and quantity were assessed with a Nanodrop 
spectrometer (ND-1000, Thermo Scientific, Wilmington, DE) using ND-1000 V3.8.1 
software. cDNA was synthesized using a Qiagen QuantiTect Reverse Transcription Kits.  
PCR reaction was performed using iTag Universal Probes Supermix, with  CYP1a1 and 
GAPDH primers Taqman probe sets on a Bio-Rad CFX384TM Real-Time System 
(Hercules, CA). CYP1a1 expression level was determined using 2-∆∆Ct methods. 
Statistical analysis 
Concentration-response analyses were performed on SigmaPlot 11.0 software (Systat 
Software Inc., San Jose, CA) using a Four Parameter Logistic Curve. Other statistical 
analyses performed using Graphpad Prism software (GraphPad Software Inc., La Jolla, 
CA). All data were normalized to uninduced control group. Data are presented as mean ± 
SEM. Statistical evaluation of the data was performed using one-way analysis of variance 
(ANOVA) followed by the Dunnett’s post hoc test to compare all groups with the control 
sample for multiple groups. For all statistical comparisons, p-values of less than 0.05 were 







Concentration-response curves for the luciferase assay activated by TCDD 
Based on the concentration-response data, TCDD displayed an EC50 value of 0.4 ± 0.1 
nM in HepG2 cells, whereas the EC50 value in Hepa1c1c7 cells was 0.03 ± 0.01 nM (Fig. 
4.1 A&B). TCDD was much more potent, and induced luciferase activity to a significantly 
greater level in HepG2 cells (maximal response 83-fold compared to uninduced control 
group) compared to Hepa1c1c7 cells (maximal response 2.2-fold compared to uninduced 
control group).  
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                          EC50 = 0.4 ± 0.1 nM                                     EC50 = 0.03 ± 0.01 nM 
 
Figure 4.1 Concentration-response curves for the luciferase assay activated by TCDD. 
AhR-dependent luciferase activity in HepG 2 cells (A) and Hepa1c1c7 cells (B) treated 







Concentration-response curves for the luciferase assay and Cyp1a1 expression activated 
by non-ortho PCB 126  
Because PCB 126 is thought to be the congener with the greatest contribution to the 
overall TEQ provided by PCBs, we examined the concentration dependence in both human 
HepG2 cells and mouse Hep1c1c7 cells. Our results show that PCB 126 had an EC50 value 
of 250 ± 150 nM in HepG2 cells, while EC50 value in Hepa1c1c7 cells was 4.7 ± 3.2 nM 
(Fig. 4.2 A&B).  PCB 126 induced luciferase activity to a significantly greater level in 
HepG2 cells (maximal response 31.6-fold compared to uninduced control group) compared 
to Hepa1c1c7 cells (maximal response 5.9-fold compared to uninduced control group).  
Using primary human and mouse hepatocytes, real-time PCR was used to measure 
CYP1A1 and Cyp1a1 mRNA levels, respectively, when treated with PCB 126. PCB 126 
induced expression of CYP1A1 with an EC50 value of 195 ± 35 nM in primary human 
hepatocytes. The EC50 value for Cyp1a1 in primary mouse hepatocytes was 12.3 ± 7.9 nM 
(Fig. 4.2 C&D). The maximal fold Cyp1a1 mRNA induction did not display a significant 
difference between primary human (45.1-fold compared to uninduced control group) and 
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            C                                                                 D 
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Figure 4.2 Concentration-response curves for the luciferase assay and Cyp1a1 expression 
activated by non-ortho PCB 126. AhR-dependent luciferase activity in HepG2 cells (A) 
and Hepa1c1c7 cells (B) treated with various of indicated concentration of PCB 126. AhR 
target gene Cyp1a1 induction in primary human (C) and mouse (D) hepatocytes after the 







Concentration-response curves for the luciferase assay activated by non-ortho PCB 169  
PCB 169 was tested using the reporter gene assay, in which HepG2 and Hepa1c1c7 
cells were treated with various of concentrations of PCB 169 up to 10 µM (Fig. 4.3 A&B). 
Based on the concentration-response data, the EC50 value was 25.7 ± 4.6 nM in Hepa1c1c7 
cells, whereas the EC50 value in HepG2 cells could not be determined, because of the failure 
to reach the maximum effect. 
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                                  EC50 = None                                                   EC50 = 25.7 ± 4.6 nM                                      
 
Figure 4.3 Concentration-response curves for the luciferase assay activated by non-ortho 
PCB 169. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) 










Concentration-response curves for the luciferase assay activated by non-ortho PCB 81 
Unlike others dioxin-like PCB congeners, PCB 81 had approximately 5-fold higher 
EC50 value in Hepa1c1c7 cells (32.0 ± 17.7 nM), compared to the EC50 value in HepG2 
cells (6.8 ± 2.7 nM) (Fig. 4.4 A&B). 
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                           EC50 = 6.8 ± 2.7 nM                                             EC50 = 32.0 ± 17.7 nM 
 
Figure 4.4 Concentration-response curves for the luciferase assay activated by non-ortho 
PCB 81. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) 











Concentration-response curves for the luciferase assay activated by mono-ortho PCB 114  
PCB 114 induced luciferase activity to a significantly greater level in HepG2 cells, 
compared to Hepa1c1c7 cells. Based on the concentration-response data, the EC50 value of 
PCB 114 was 796 ± 661 nM in Hepa1c1c7 cells, whereas the EC50 value in HepG2 cells 
was not attained because of the inability to reach the maximal effects, like PCB 169 (Fig. 
4.5 A&B). 
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                               EC50 = None                                                 EC50 = 796.5 ± 660.5 nM 
 
Figure 4.5 Concentration-response curves for the luciferase assay activated by mono-ortho 
PCB 114. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) 









Concentration-response curves for the luciferase assay activated by non-ortho PCB 77 
PCB 77 induced luciferase activity to a higher level in HepG2 cells, compared to 
Hepa1c1c7 cells. The EC50 value for PCB 77 was 108 ± 39 nM in Hepa1c1c7 cells, whereas 
EC50 value in HepG2 cells was again not attained because of failure to reach the maximal 
effect (Fig. 4.6 A&B).  
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                            EC50 = None                                                EC50 = 108.2 ± 38.8 nM 
 
Figure 4.6 Concentration-response curves for the luciferase assay activated by non-ortho 
PCB 77. AhR-dependent luciferase activity in HepG2 cells (A) and Hepa1c1c7 cells (B) 










DL/NDL-PCBs mixture activates mouse AhR  
HepG2 and Hepa1c1c7 cells were transfected with AhR-dependent (pXRE-SV40-Luc) 
reporter plasmid, then treated with Aroclor 1260 (10 µg/ml), Aroclor 1254 (10 µg/ml), 
PCB 126 (3.26 µg/ml; 10 µM), or the DL/NDL-PCBs mixture (Aroclor 1260 (10 µg/ml) 
plus 0.1 % PCB 126 (10 ng/ml; 0.0306 µM), Aroclor 1260/PCB 126), and positive control 
1,2-benz[a]anthracene (BA, 2.28 µg/ml; or 50 µM). These concentrations have been shown 
not to cause cellular toxicity (52). As anticipated, BA increased luciferase activity 67.4-
fold in HepG2 cells and 5.1-fold in Hepa1c1c7 cells when compared with vehicle group. 
Likewise, PCB 126 induced a 42.2-fold increase in luciferase activity in HepG2 cells and 
a 3.7-fold increase in Hepa1c1c7 cell lines. Neither Aroclor 1260 nor Aroclor 1254 induced 
luciferase activity in either HepG2 or Hepa1c1c7. In contrast, the mixture of Aroclor 
1260/PCB 126 induced luciferase in only the Hepa1c1c7 cell line by 3.0-fold. It is 
important to note that the concentration of PCB 126 (0.0306 µM) is much lower in the 
DL/NDL-PCBs mixture than the 10 µM used as a control (Fig. 4.7 A&B).    
The expression of the prototypical AhR target gene CYP1a1 was measured using RT-
PCR in primary human and mouse hepatocytes treated with chemicals of interest. As 
anticipated, BA increased the expression of CYP1A1 message 616-fold in human primary 
hepatocytes and 398-fold in murine primary hepatocytes. Likewise, addition of 10 µM PCB 
126 induced CYP1A1 message 225-fold in human hepatocytes and 187-fold in murine 
hepatocytes. Neither Aroclor 1260 nor Aroclor 1254 induced mRNA expression of either 
CYP1A1 or Cyp1a1 in human and murine hepatocytes, respectively. Consistent with the 
luciferase assay results, the DL/NDL-PCBs mixture group showed no significant elevation 
of CYP1A1 mRNA expression in primary human hepatocytes, but exhibited markedly 
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increased expression of Cyp1a1 message in primary mouse hepatocytes (112-fold) (Fig. 
4.7 C&D). These data demonstrated that regardless of using isolated hepatocytes or 
immortalized cell lines, the trends are consistently similar among these treatments. The 
results suggested that the maximal response of human AhR was higher than that of mouse 
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Figure 4.7 DL/NDL-PCBs mixture activates mouse AhR. AhR-dependent luciferase 
activity in HepG2 cells (A) and Hepa1c1c7 cells (B) treated with Aroclor 1260 (10 µg/ml), 
Aroclor 1254 (10 µg/ml), PCB 126 (10 µM), DL/NDL-PCBs mixture (Aroclor 1260 (10 
µg/ml) plus 0.1 % PCB 126 (10 ng/ml; 0.0306 µM), Aroclor 1260/PCB 126), and positive 
control 1,2-benz[a]anthracene (BA, 10 µM). AhR target gene CYP1a1 induction in primary 
human (C) and mouse (D) hepatocytes after the same treatment with luciferase activity 







The main objective of the current study was to test the hypothesis that DL-PCBs 
exhibited higher concentration-dependence for the mouse AhR activation than for human 
AhR. Neither, Aroclor 1260 nor 1254 activated AhR or induced AhR-dependent gene 
expression in either cell line, suggesting that the major PCB congeners in this mixture are 
not effective AhR ligands. This was expected for Aroclor 1260 as it contains low levels of 
DL-PCBs and requires exposures over 20 mg/kg to induce Cyp1a2 in murine whole animal 
models (59). In contrast, we expected Aroclor 1254 would activate AhR as it contains more 
penta- and less-highly chlorinated PCBs than the hexa- and hepta-substituted PCBs that 
predominate in Aroclor 1260; therefore, Aroclor 1254 should have higher levels of DL-
PCBs. The amounts of DL-PCBs in Aroclor 1254 varies considerably (142) by lot and we 
used lot 124-191 rather than lots like lot 6024 which contains approximately 10-fold higher 
DL-PCBs. Thus, it is possible that induction may have been observed with Aroclor 1254, 
had we used another lot. 
We designed a DL/NDL-PCBs mixture containing more dioxin-like congeners 
(Aroclor 1260 plus 0.1% PCB 126) to approximate the human PCB exposure profiles seen 
in the general U.S. population (98). We found that this fortified DL/NDL-PCBs mixture 
activated AhR in murine cells, but failed to induce human AhR in transfection experiments 
in immortalized cell lines and in primary human or mouse hepatocytes. This suggests that 
the affinity values for DL-PCBs, i.e., EC50 values, are considerably lower in murine 
systems than in human cells (Table 4.1). 
As anticipated, PCB 126, the most potent DL-PCB ligand for the AhR, increased AhR 
luciferase activity in immortal cells or increased Cyp1a1 mRNA levels in primary 
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hepatocytes regardless of species at 10 µM. The fold induction with either BA or PCB 126 
was significantly lower in the Hepa1c1c7 cell line than in the HepG2 cell line, but similar 
in the primary hepatocytes.  This most likely is a cell line-dependent effect, possibly as a 
result of a rapid decrease in AhR protein after translocation to the nucleus in Hepa1c1c7 
cells (143). The more relevant fold-inductions from primary mouse and human hepatocytes 
were similar. This likely reflects similarities in the activation domains between the two 
receptors and similarities in the number and sequence of the AhR responsive elements of 
either CYP1A1 or Cyp1a1. 
In this study, the EC50 value for TCDD in both cell lines was not similar, 0.4 ± 0.1 nM 
in HepG2 cells and 0.03 ± 0.01 nM in Hepa1c1c7 cells. This was approximately 4-fold 
higher than previously published studies (144-146).   
The EC50-based potencies for DL-PCBs in HepG2 cells in rank order was TCDD > 
PCB 81 > PCB 126, consistent with previous studies (136)  that used CYP 1A1 activity 
assays to determine EC50-based potencies in HepG2 cells (Table 4.2). The EC50-based 
relative potency values (REPs) were calculated (Table 4.2). In HepG2 cells, the REPs of 
PCB 126 and PCB 81were 0.002 and 0.06, respectively within species, consistent with 
previous studies (136).  The EC50 values of various DL-PCB congeners were lower in 
Hepa1c1c7 cells except for PCB 81 that displayed a lower EC50 in HepG2 cells than PCB 
126, but a higher EC50 in Hepa1c1c7 cells. The rank order of EC50-based potencies in 
mouse Hepa1c1c7 cells was TCDD > PCB 126 > PCB 169 > PCB 81 > PCB 77 > PCB 
114 (145).  This is nearly identical to results observed with the rat H4IIE cell line (136). In 
our study with Hepa1c1c7 cells, the REPs in table 4.2 for PCB 126 was 0.006, PCB 81 was 
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0.0009, PCB 77 was 0.0003, PCB 114 was 0.00004, and PCB 169 was 0.001 which are 
much lower than the rat REPs. 
In contrast to the mouse and human REPs, the rat REPs are reported to be much higher 
for DL-PCBs in rat H4IIE cells and rat primary hepatocytes. The WHO 2005 TEF values 
are based on a combination of rodent and human REPs. The species most commonly used 
in PCB studies is the rat, so the WHO 2005 TEF values likely reflect this and may vary 
considerably from that observed in humans. With TEF, the toxicity of a mixture of dioxins 
or dioxin-like chemicals could be defined by the toxic equivalency (TEQ); it can be 
calculated by the sum of the concentrations of individual chemicals (Ci) multiplied by their 
relative toxicity (TEF). Thus, the WHO 2005 TEF for PCB 126 is 0.1, far higher than our 
human REP of 0.002. In contrast to the PCBs, published consensus toxicity factors for 
polychlorinated dibenzo-p-dioxins and dibenzofurans (145) are much more closely aligned 
to WHO 2005 TEFs, suggesting that the human TEQ may represent a result dominated by 
these compounds with PCBs having only a small effect. Of relevance to humans, the PCB 
load we receive from food consumption (147) in which PCBs make up approximately 30 % 
of the TEQ using WHO 2005 TEFs. If this where adjusted using our REPs and that of 
others (145), it would only be a few percent at best.  
Likewise, in our previous animal studies (59), Aroclor 1260 made steatohepatitis 
worse in animals fed a high fat diet at exposures that did not appear to significantly induce 
Cyp1a2 gene expression. In mice, the different AhR ligands activate different subsets of 
genes leading to the concept of selective modulation of the AhR (148) and it is unclear 
whether the human AhR behaves in a similar manner. As the human AhR has higher 
affinity for either dietary indole metabolites or tryptophan metabolites than the mouse AhR 
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(149), it may be important to determine whether PCBs act like the dietary and endogenous 
ligands or like dioxin-like compounds.  
In summary, the results demonstrated the sensitivity of mouse AhR, as indicated by 
lower EC50 value, is higher than human AhR in response to dioxin exposure and even more 
so with DL-PCBs like PCB 126. In addition, the DL/NDL-PCBs mixture designed to 
approximate human exposures and bioaccumulation patterns activated the mouse AhR, but 
not the human AhR. These results suggest that the animal exposure models in chapter 2 
and 3 should be referred to increase human relevance. This could be accomplished by using 




















Table 4.1 AhR EC50 values in human and mouse 









TCDD  0.4±0.1 0.03±0.01 n.d. n.d. 
PCB 77 n n.d.b 108.2 ±38.8 n.d. n.d. 
PCB 81 n 6.8±2.7 32.0±17.7 n.d. n.d. 
PCB 126 n 250±150 4.7±3.2 194.5±35.2 12.3±7.9 
PCB 169 n n.d. 25.7 ±4.6 n.d n.d 
PCB 114 m n.d. 796.5 ±660.5 n.d n.d 
 
Note. EC50 values calculated 24 hours after treatment with TCDD and DL-PCB 
congeners. 
a n means non-ortho; m means mono-ortho. 
b n.d. means not/no detectable.  
 
Table 4.2 Relative Effect Potency Values (REPs) 
Chemical Type a HepG2 Hepa1c1c7 WHO-TEF c 
TCDD  1 1 1 
PCB 77 n n.d.b 0.0003 0.0001 
PCB 81 n 0.06 0.0009 0.0003 
PCB 126 n 0.002 0.006 0.1 
PCB 169 n n.d. 0.001 0.03 
PCB 114 m n.d. 0.00004 0.00003 
 
a n means non-ortho; m means mono-ortho. 
b n.d. means not/no detectable.  






1. Overall goals and specific aims 
The goals of the current dissertation are to investigate and compare low doses of DL-
PCB congener (PCB 126, 20 µg/kg), NDL-PCBs mixture (Aroclor 1260, 20 mg/kg), and 
DL/NDL-PCBs mixture exposure (mixture of Aroclor 1260 and PCB 126)-induced 
NAFLD/NASH and metabolic dysfunction, as well as, to investigate the role of AhR in 
PCBs exposure-induced NAFLD/NASH. The outcomes of these studies have provided us 
a better understanding of different PCB exposures-induced NAFLD/NASH. The specific 
aims are shown as follows: 
Specific Aim 1 addressed whether DL-PCBs, NDL-PCBs, and DL/NDL-PCBs act 
differently on fatty liver disease. 
1a. Determined the activation of AhR and liver injury stimulated by DL-PCB and 
DL/NDL-PCBs mixture in a two-week treatment in mice on control synthetic diet. 
1b. Determined the effects of DL-PCB and DL/NDL-PCBs mixture in NAFLA/NASH in 
a twelve-week treatment in mice on high fat diet via interaction with AhR. 
Specific Aim 2 addressed whether human and murine AhR display the same concentration-
dependence for ligand activation in response to PCBs.   
2a. Determined the half maximal effective concentration (EC50) for DL-PCB congeners in 
HepG2 cells and Hepa1c1c7 cells transfected with a XRE-luciferase reporter.
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2b. Determined the concentration-dependence of AhR activation in murine and human 
primary hepatocytes treated with DL-PCBs and DL/NDL-PCBs mixture. 
2. Major findings of current dissertation 
In my dissertation, specific aim 1 addressed whether DL-PCBs, NDL-PCBs, and 
DL/NDL-PCBs act differently on fatty liver disease. A new human relevant PCB exposures 
animal model was established to evaluate different outcomes of DL-, NDL-, and DL/NDL-
PCBs mixture exposure in NAFLD/NASH. In the control synthetic diet acute PCB 
exposures model, DL-PCB 126 exposure induced AhR activation, and caused mild hepatic 
steatosis (lean NAFLD), and DL/NDL-PCBs mixture exposure targeted pancreas, and 
caused pancreatic dysfunction, a condition termed PCB exposure-induced pancreatopathy. 
In high fat diet chronic PCB exposures model, Aroclor 1260 promoted steatosis 
progression to steatohepatitis (obese NASH), while DL-PCB 126 attenuated Aroclor 1260 
exposure-induced steatohepatitis. Novel mechanisms of PCB exposures-induced toxicity 
related to NAFLD/NASH, such as liver-pancreas axis, β cell identity, hepatokines, and 
Pnpla3 were observed in the animal models. Please refer to supplemental table 1 &2 for 
detailed information. Specific aim 2 addressed whether human and murine AhR display 
the same concentration-dependence for ligand activation in response to PCBs. The results 
demonstrated that the concentration-dependence of mouse AhR activation by DL-PCBs is 
much lower than human AhR, suggesting species difference for AhR activation, and the 
same difference was also found in REPs in response to PCBs exposure. Difference between 
human and mouse AhR relative ligand affinity indicated that humanized AhR mouse model 




3. Strengths and limitations of this dissertation 
Strengths 
There are several strengths in this dissertation. First strength is environmentally 
relevant DL/NDL-PCBs mixture exposure induces AhR activation in vivo, and the extent 
of AhR activation by this PCBs mixture is similar to low dose of PCB 126 exposure, and 
the histological changes and molecule level of lipid metabolism gene expression are 
different with this PCBs mixture exposure compared to either exposure alone. This result 
may be due to the interaction of transcription factors, as well as diet effects. In addition, 
DL/NDL-PCBs mixture also induces pancreatic structure changes and dysfunction, termed 
PCBs exposure-induced pancreatopathy. These data suggest to us that DL/NDL-PCBs 
mixture should be used when we evaluate a PCB exposures-induced metabolic disease, 
providing data that more closely reflect in human. Another strength is that our AhR relative 
ligand affinity assay demonstrates activation of mouse AhR is much more sensitive to dose 
than human AhR by dioxin-like PCB congeners exposure. Moreover, DL/NDL-PCBs 
mixture at the concentration tested only activates mouse AhR, not human AhR. These data 
suggest a species difference between human and mouse that should be considered when 
evaluating the risk of PCBs mixture exposure that contain dioxin-like PCB congeners, and 
the data generated could provide us better understanding of PCB exposure-induced disease 
in humans.  
Limitations 
Although the phenotypic changes are significantly different by specific PCB exposures, 
we will not be able to provide a molecular mechanism that is responsible for these changes. 
However, our results suggest nuclear receptor, AhR, hepatokines, and Pnpla3 could be 
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influenced. A proteomic and/or RNA sequencing analysis could be done to identify 
different proteins and/or genes that might provide us an insight for these phenotypical 
changes. PCB exposures-induced AhR, PXR, and CAR activation, were associated with 
phenotypic changes; however, the exact role of these receptors’ activation in PCB 
exposures-induced liver disease is unclear. In addition, potential sex differences were also 
not considered in this dissertation, as PCBs interact with estrogen receptor (51) and AhR 
activation causes loss of liver specific and sexually dimorphic gene expression (150). AhR 
is also expressed in gut, and may impact liver disease through gut-liver axis. Thus, the 
hepatocyte AhR-specific knockout mice, and/or combination with CAR/PXR double 
knockout mice might be used to better understand the potential mechanisms. (151). 
Moreover, PCBs exposure disrupts intestinal integrity (152) and induces dysbiosis of the 
gut microbiota (153, 154). Therefore, investigation of gut microbiota would be performed 
with the varying PCB exposures. These data may distinguish the causative of various of 
changes by different PCB exposures. Lastly, the humanized AhR mouse should be used to 
better evaluate risk of PCBs exposure, due to the different AhR relative ligand affinity 
across species.  
4. Summary  
Taken together, both PCB 126 or the DL/NDL-PCBs mixture activated AhR, while 
Aroclor 1260 exposure activated CAR and PXR in either control synthetic diet or high fat 
diet. However, high fat diet abrogated PCB exposures-induced xenobiotic receptor 
activation. The effects of PCB exposures on liver lipid homeostasis were summarized in 
Figure 5.1. PCB 126 exposure induced mild hepatic steatosis in control synthetic diet 
model (lean NAFLD), while Aroclor 1260 exposure promoted steatosis progression to 
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steatohepatitis (obese NASH) in high fat diet model. Regardless of the diet effects, PCB 
exposures increased lipid influx to liver, and decreased de novo lipogenesis. Moreover, 
PCB 126 exposure decreased fasting blood glucose via inhibition of hepatic gluconeogenic 
gene mRNA expression, and induced hypolipidemia. For fatty acid β-oxidation, PCB 
exposures exhibited different effects on mRNA expression for these genes. Other potential 
mechanisms include hepatokines, Pnpla3 mRNA transcription. The DL/NDL-PCBs 
mixture caused pancreatopathy which warrant future study. Difference in ligand 
concentration-dependence of AhR activation between human and mouse was observed by 
DL-PCB congeners exposure, and DL/NDL-PCBs mixture exposure activated mouse AhR. 
These results suggested that utilizing an environmentally relevant mixture of PCBs 
containing both DL-and NDL-PCB congeners is important in the study of endocrine and 
metabolic disruption because the combined effects may be different than the effects of 
either type of PCB alone. Due to species difference in PCB-ligand activation of AhR, 




















Supplemental Table 1 Effects of PCB exposures on liver, pancreas and blood in mice fed 
on control synthetic diet for 2 weeks. 







↔ ↑ ↑ 
Cyp2b10 
induction 
↑ (+/+) ↑ (-/-) ↑ (+/-) * 
Cyp3a11 
induction 
↑ ↔ ↔ * 
Steatosis ↔ ↑ ↔ * 
Injury ↔ ↔ ↔ 
Lipid uptake gene 
 mRNA levels 
↑ ↑ ↔ * 
Fatty acid β-oxidation gene 
mRNA levels 
↔ ↑ ↔ * 
Fatty acid synthesis gene 
mRNA levels 





FGF21 ↓ ↓ ↑ * 
IGF1 ↑ ↑ ↔ * 
Betatrophin ↑ ↔ ↓ * 
Gluconeogenesis gene 
mRNA levels 
↔ ↓ ↔ * 
Pancreas Atrophy ↔ ↔ ↑ 
Acinar cell steatosis ↔ ↔ ↑ 
Fibrosis ↔ ↔ ↑ 
Insulin1 gene mRNA levels ↑ ↑ ↓ * 
Pancreatic polypeptide 
gene mRNA levels 
↑ ↑ ↓ * 
Islet identity gene mRNA 
levels 
↑ ↑ ↓ * 
Blood Fasting glucose ↔ ↓ ↓ 
Lipid ↔ ↓ ↓ 
Insulin ↔ ↔ ↔ 
Systemic inflammation ↔ ↔ ↔ 
 
Notes: 
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus vehicle 
control;  
2. + indicates numerical high; - indicates numerical low; 
3. * indicates interaction between Aroclor 1260 and PCB 126.  
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Supplemental Table 2 Effects of PCB exposures on liver and blood in mice fed on high 
fat diet for 12 weeks. 
Targets Effects Aroclor 
1260 







↔ ↑ ↑ * 
Cyp2b10 
induction 
↑ (+) ↔ ↑(-) * 
Steatosis ↔ ↔ ↔  
Injury ↑ ↓ ↓ 
Inflammation ↑ ↔ ↔* 
Lipid uptake gene mRNA 
levels 
↑ ↑ ↑ 
Fatty acid β-oxidation gene 
mRNA levels 
↓ ↓ ↓ 
Fatty acid synthesis gene 
mRNA levels 




↔ ↓ ↓ 
Phenotype ↔ ↔ ↔ 
Gluconeogenesis gene 
mRNA levels 
↔ ↓ ↔  
Blood Fasting glucose ↔ ↓ ↓ 
Lipid (triglyceride) ↔ ↓ ↓ 
Adipokines ↔ ↔ ↔ 
Tolerance test ↔ ↔ ↔ 
 
Notes: 
1. ↔ indicates no change; ↑ indicates increase; ↓ indicates decrease versus vehicle 
control;  
2. + indicates numerical high; - indicates numerical low; 
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AhR Aryl hydrocarbon receptor 
ARNT AhR nuclear translocator 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
BA 1,2-benz[a]anthracene 
CAR Constitutive androstane receptor 
CCL8 Chemokine (C-C motif) ligand 8 
Cpt1α Carnitine palmitoyl transferase 1A 
CXCL1 Chemokine (C-X-C motif) ligand 1 
CYP Cytochromes P450 
CITCO 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5- 
carbaldehydeO-(3,4dichlorobenzyl)oxime 
DL Dioxin like 
DMSO Dimethyl sulfoxide 
DRE Dioxin-responsive element 
ECM Extracellular matrix 
EDCs/MDCs Endocrine and metabolism disrupting chemicals 
FABP1 Fatty acid-binding protein 1 
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FASN Fatty acid synthase 
FGF21 Fibroblast growth factor 21 
FoxO1 Forkhead box protein O1 
G6P Glucose 6-phosphate 
GTT Glucose tolerance test 
HCC Hepatocellular carcinoma 
HDL High-density lipoprotein 
HNF4α Hepatocyte nuclear factor 4 alpha 
HFD High fat diet 
IGF1 Insulin-like growth factor 1 
IL6 Interleukin 6 
ITT Insulin tolerance test 
LDL Low-density lipoprotein 
MCP1 Monocyte chemoattractant protein 1 
MCD Methionine choline-deficient 
MMPs Matrix metalloproteases 
NAFLD/NASH Nonalcoholic fatty liver disease /steatohepatitis 
NDL Non-dioxin like 
nHDLc non-HDL cholesterol 
NR Nuclear receptor 
PAI1 Plasminogen activator inhibitor-1 
PCB Polychlorinated biphenyl 
Pck1 Phosphoenolpyruvate carboxy kinase 
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PGC1α Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha 
PNPLA3 Patatin-like phospholipase domain-containing protein 3 
PPARα Peroxisome proliferator-activated receptor alpha 
PXR Pregnane X receptor 
RT-PCR Reverse transcription-polymerase chain reaction 
SCD1 Stearoyl coenzyme A desaturase1 
TAFLD/TASH Toxicant associated fatty liver disease/steatohepatitis 
TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TCPOBOP 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene 
TIMPs Tissue inhibitors of metalloproteinases 
TNFα Tumor necrosis factor-alpha 
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